Clinical trial results:
A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed

Summary

EudraCT number	2015-004401-17
Trial protocol	DE GB ES BE NL
Global end of trial date	03 May 2022

Results information

Result version number	v6 (current)
This version publication date	02 August 2023
First version publication date	02 May 2020
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	204862

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, ViiV Healthcare, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 June 2022
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	03 May 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the non-inferior antiviral activity of switching to DTG +3TC once daily compared to continuation of TBR over 48 weeks in HIV-1 infected, ART therapy (ART)-experienced, virologically suppressed participants.

Protection of trial subjects:

Not Applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 January 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 40
Country: Number of subjects enrolled	Belgium: 25
Country: Number of subjects enrolled	Canada: 25
Country: Number of subjects enrolled	France: 26
Country: Number of subjects enrolled	Germany: 83
Country: Number of subjects enrolled	Japan: 11
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Spain: 229
Country: Number of subjects enrolled	United States: 286
Country: Number of subjects enrolled	United Kingdom: 13
Worldwide total number of subjects	743
EEA total number of subjects	368

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	726
From 65 to 84 years	17
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study evaluated antiviral activity of switching to dolutegravir(DTG)+lamivudine(3TC) fixed dose combination(FDC) once daily compared to continuation of Tenofovir alafenamide (TAF)-based regimen(TBR)over 148weeks in participants with human immunodeficiency type 1 infection. At week148 all participants received DTG+3TC FDC until week 196.

Pre-assignment

Screening details:

A total of 743 participants were randomized to receive treatment. Two participants in the DTG+3TC group were randomized but not treated. A total of 741 participants received at least one dose of study treatment either DTG + 3TC or TBR creating the intent to treat-exposed (ITT-E) Population.

Period 1

Period 1 title	Early Switch Phase (Day 1 to week 148)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG+3TC FDC

Arm description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) less than (<)50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg in early switch phase (Day 1 to Week 148) and continued to receive DTG/3TC FDC in late switch phase (Week 148 to Week 196).

Arm type	Experimental
Investigational medicinal product name	Dolutegravir (DTG)+Lamivudine (3TC) fixed dose combination (FDC)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received DTG 50 milligrams (mg) + 3TC 300 mg FDC as a white, oval and film-coated tablet. The tablets were packed in high density polyethylene (HDPE) bottles with induction seals, 2 grams (gm) desiccant, and child resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets.

Arm title	TAF-based regimen

Arm description:

Participants who were on a stable TBR and had an HIV-1 RNA<50 c/mL at the time of screening received TBR up to Week 148 in early switch phase, these participants were switched to DTG/3TC FDC in late switch phase (Week 148 to Week 196). One participant randomized to this arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm (early switch phase) for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen"arm (early switch phase) for Safety because the safety profiles of TDF and TAF differ.

Arm type	Active comparator
Investigational medicinal product name	Tenofovir alafenamide (TAF) based regimen (TBR)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants continued to receive stable TBR

Number of subjects in period 1[1]	DTG+3TC FDC	TAF-based regimen
Started	369	372
Completed	319	299
Not completed	50	73
Adverse event, serious fatal	3	-
Physician decision	2	11
Consent withdrawn by subject	16	33
Adverse event, non-fatal	20	7
Lost to follow-up	4	10
Protocol deviation	5	6
Lack of efficacy	-	6

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: One participant was not switched to DTG+ 3TC FDC due to being lost to follow up post Week 148 visit, hence did not enter in the late switch phase

Period 2

Period 2 title	Late Switch Phase (Week 148 to Week 196)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG+3TC FDC

Arm description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) less than (<)50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg in early switch phase (Day 1 to Week 148) and continued to receive DTG/3TC FDC in late switch phase (Week 148 to Week 196).

Arm type	Experimental
Investigational medicinal product name	Dolutegravir (DTG)+Lamivudine (3TC) fixed dose combination (FDC)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received DTG 50 milligrams (mg) + 3TC 300 mg FDC as a white, oval and film-coated tablet. The tablets were packed in high density polyethylene (HDPE) bottles with induction seals, 2 grams (gm) desiccant, and child resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets.

Arm title	TAF-based regimen

Arm description:

Participants who were on a stable TBR and had an HIV-1 RNA<50 c/mL at the time of screening received TBR up to Week 148 in early switch phase, these participants were switched to DTG/3TC FDC in late switch phase (Week 148 to Week 196). One participant randomized to this arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm (early switch phase) for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen"arm (early switch phase) for Safety because the safety profiles of TDF and TAF differ.

Arm type	Active comparator
Investigational medicinal product name	Tenofovir alafenamide (TAF) based regimen (TBR)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants continued to receive stable TBR

Number of subjects in period 2[2]	DTG+3TC FDC	TAF-based regimen
Started	319	298
Completed	307	274
Not completed	12	24
Adverse event, serious fatal	1	-
Consent withdrawn by subject	4	6
Physician decision	-	1
Adverse event, non-fatal	1	9
Lost to follow-up	5	6
Lack of efficacy	1	1
Protocol deviation	-	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: A total of 743 participants were enrolled, of which two participants did not receive treatment and hence 741 participants received at least one treatment in the study.

Baseline characteristics

Reporting groups	
Reporting group title	DTG+3TC FDC
Reporting group description:	
Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) less than (<)50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg in early switch phase (Day 1 to Week 148) and continued to receive DTG/3TC FDC in late switch phase (Week 148 to Week 196).	
Reporting group title	TAF-based regimen
Reporting group description:	
Participants who were on a stable TBR and had an HIV-1 RNA<50 c/mL at the time of screening received TBR up to Week 148 in early switch phase, these participants were switched to DTG/3TC FDC in late switch phase (Week 148 to Week 196). One participant randomized to this arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm (early switch phase) for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen"arm (early switch phase) for Safety because the safety profiles of TDF and TAF differ.	

Reporting group values	DTG+3TC FDC	TAF-based regimen	Total
Number of subjects	369	372	741
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total	369	372	741
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean	40.6	40.9	
standard deviation	± 10.76	± 11.54	-
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female	25	33	58
Male	344	339	683
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native	7	8	15
Asian-Central/South Asian Heritage (H)	3	4	7
Asian-Japanese H/East Asian H/South East Asian H	10	9	19
Black or African American	50	58	108
Native Hawaiian or other Pacific Islander	1	3	4
White-Arabic/North African (NA) H	5	2	7
White-Arabic/NA H and white/caucasia/European H	0	1	1
White-White/caucasian/European H	292	286	578
Asian and White	0	1	1
Black or African American and White	1	0	1

HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1	255	259	514
HIV infection Stage 2	94	94	188
HIV infection Stage 3	20	19	39
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI	51	48	99
INSTI	289	296	585
PIs	29	28	57
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3)			
median	682.0	720.0	
inter-quartile range (Q1-Q3)	492.0 to 862.0	531.5 to 901.5	-

Subject analysis sets

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized

to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	Randomized to TBR But Received TDF-based Regimen(Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participant randomized to TBR arm who had HIV-1 RNA <50 c/mL at the time of screening, received TDF-based regimen instead of TAF-based regimen in error. Participant continued to receive TDF-regimen up to the Week 48 visit (participant withdrew from the study at Week 36)

Subject analysis set title	DTG+3TC FDC (Early switch)

Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase

Subject analysis set title	Randomized to TBR But Received TDF-based Regimen(Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participant randomized to TBR arm who had HIV-1 RNA <50 c/mL at the time of screening, received TDF-based regimen instead of TAF-based regimen in error. Participant continued to receive TDF-regimen up to the Week 48 visit (participant withdrew from the study at Week 36).

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 48 weeks.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 48 weeks. One participant randomized to the this arm received TDF rather than TAF-and was presented within the “TAF-based regimen” arm for efficacy because the efficacy of TAF and TDF are comparable. However the participant was presented separately under “TDF-based regimen” for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early Switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Reporting group values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)	DTG+3TC FDC (Early switch)
Number of subjects	369	372	344
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean	0.3	0.5	93.2
standard deviation	±	±	±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female			
Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native			
Asian-Central/South Asian Heritage (H)			
Asian-Japanese H/East Asian H/South East Asian H			
Black or African American			
Native Hawaiian or other Pacific Islander			
White-Arabic/North African (NA) H			
White-Arabic/NA H and white/caucasia/European H			
White-White/caucasian/European H			
Asian and White			
Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an			

AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1 HIV infection Stage 2 HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3)			
median inter-quartile range (Q1-Q3)	0.3	0.5	93.2

Reporting group values	TAF Based Regimen (Early switch)	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)
Number of subjects	346	369	372
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean	93.0		
standard deviation	±	±	±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native Asian-Central/South Asian Heritage (H) Asian-Japanese H/East Asian H/South East Asian H Black or African American Native Hawaiian or other Pacific Islander White-Arabic/North African (NA) H White-Arabic/NA H and white/caucasia/European H White-White/caucasian/European H			

Asian and White Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1 HIV infection Stage 2 HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3) median inter-quartile range (Q1-Q3)	 93.0 		

Reporting group values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)	TAF Based Regimen (Early switch)
Number of subjects	350	358	371
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years arithmetic mean standard deviation	 95 ±	 96 ±	 ±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native Asian-Central/South Asian Heritage (H)			

Asian-Japanese H/East Asian H/South East Asian H Black or African American Native Hawaiian or other Pacific Islander White-Arabic/North African (NA) H White-Arabic/NA H and white/caucasia/European H White-White/caucasian/European H Asian and White Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1 HIV infection Stage 2 HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3)			
median	95	96	
inter-quartile range (Q1-Q3)			

Reporting group values	TAF Based Regimen (Early switch)	Randomized to TBR But Received TDF-based Regimen(Early	DTG+3TC FDC (Early switch)
Number of subjects	371	1	369
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean			23
standard deviation	±	±	±

Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native Asian-Central/South Asian Heritage (H) Asian-Japanese H/East Asian H/South East Asian H Black or African American Native Hawaiian or other Pacific Islander White-Arabic/North African (NA) H White-Arabic/NA H and white/caucasia/European H White-White/caucasian/European H Asian and White Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1 HIV infection Stage 2 HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3) median inter-quartile range (Q1-Q3)			 23

Reporting group values	Randomized to TBR But Received TDF-based Regimen(Early	DTG+3TC FDC (Early switch)	DTG+3TC FDC (Early switch)
Number of subjects	1	369	369

Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean	0		
standard deviation	±	±	±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female			
Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native			
Asian-Central/South Asian Heritage (H)			
Asian-Japanese H/East Asian H/South East Asian H			
Black or African American			
Native Hawaiian or other Pacific Islander			
White-Arabic/North African (NA) H			
White-Arabic/NA H and white/caucasia/European H			
White-White/caucasian/European H			
Asian and White			
Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1			
HIV infection Stage 2			
HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI			
INSTI			
PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are			

reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3)			
median	0		
inter-quartile range (Q1-Q3)			

Reporting group values	TAF Based Regimen (Early switch)	TAF Based Regimen (Early switch)	TAF Based Regimen (Early Switch)
Number of subjects	371	1	2
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female			
Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native			
Asian-Central/South Asian Heritage (H)			
Asian-Japanese H/East Asian H/South East Asian H			
Black or African American			
Native Hawaiian or other Pacific Islander			
White-Arabic/North African (NA) H			
White-Arabic/NA H and white/caucasia/European H			
White-White/caucasian/European H			
Asian and White			
Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1			
HIV infection Stage 2			
HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at			

Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3) median inter-quartile range (Q1-Q3)			

Reporting group values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)	TAF Based Regimen (Early switch)
Number of subjects	364	370	369
Age categorical			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
Total			
Age Continuous			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Participants			
Female Male			
Race/Ethnicity, Customized			
Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
American Indian or Alaska Native Asian-Central/South Asian Heritage (H) Asian-Japanese H/East Asian H/South East Asian H Black or African American Native Hawaiian or other Pacific Islander White-Arabic/North African (NA) H White-Arabic/NA H and white/caucasia/European H White-White/caucasian/European H Asian and White Black or African American and White			
HIV infection by Centers for Disease Control and Prevention (CDC) classification			
CDC classification for human immunodeficiency (HIV) were: Stage 1: No acquired immuno deficiency syndrome (AIDS) defining condition and CD4+ T-lymphocyte count: >=500 cells per microliter (cells/mcL); Stage 2: No AIDS-defining condition and CD4 200-499; Stage 3: Documentation of an			

AIDS- defining condition or CD4 < 200cells/mcL. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
HIV infection Stage 1 HIV infection Stage 2 HIV infection Stage 3			
Baseline third agents			
Baseline third agents including non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand transfer inhibitors (INSTI) and protease inhibitors (PIs) based on the antiretroviral medications taken at Baseline. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Subjects			
NNRTI INSTI PIs			
Cluster of differentiation 4 plus (CD4+) cell count			
Blood samples were collected to evaluate Baseline CD4+ cell count using flow cytometry. Median along with first and third quartiles are presented for Baseline CD4+ count. Baseline Characteristic data are reported for participants in the ITT-E Population			
Units: Cells per cubic millimeter (cells/mm^3) median inter-quartile range (Q1-Q3)			

End points reporting groups

Reporting group title	DTG+3TC FDC

Reporting group description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) less than (<)50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg in early switch phase (Day 1 to Week 148) and continued to receive DTG/3TC FDC in late switch phase (Week 148 to Week 196).

Reporting group title	TAF-based regimen

Reporting group description:

Participants who were on a stable TBR and had an HIV-1 RNA<50 c/mL at the time of screening received TBR up to Week 148 in early switch phase, these participants were switched to DTG/3TC FDC in late switch phase (Week 148 to Week 196). One participant randomized to this arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm (early switch phase) for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen"arm (early switch phase) for Safety because the safety profiles of TDF and TAF differ.

Reporting group title	DTG+3TC FDC

Reporting group description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) less than (<)50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg in early switch phase (Day 1 to Week 148) and continued to receive DTG/3TC FDC in late switch phase (Week 148 to Week 196).

Reporting group title	TAF-based regimen

Reporting group description:

Participants who were on a stable TBR and had an HIV-1 RNA<50 c/mL at the time of screening received TBR up to Week 148 in early switch phase, these participants were switched to DTG/3TC FDC in late switch phase (Week 148 to Week 196). One participant randomized to this arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm (early switch phase) for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen"arm (early switch phase) for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening,

were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	Randomized to TBR But Received TDF-based Regimen(Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participant randomized to TBR arm who had HIV-1 RNA <50 c/mL at the time of screening, received TDF-based regimen instead of TAF-based regimen in error. Participant continued to receive TDF-regimen up to the Week 48 visit (participant withdrew from the study at Week 36)

Subject analysis set title	DTG+3TC FDC (Early switch)

Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase

Subject analysis set title	Randomized to TBR But Received TDF-based Regimen(Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participant randomized to TBR arm who had HIV-1 RNA <50 c/mL at the time of screening, received TDF-based regimen instead of TAF-based regimen in error. Participant continued to receive TDF-regimen up to the Week 48 visit (participant withdrew from the study at Week 36).

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 48 weeks.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 48 weeks. One participant randomized to the this arm received TDF rather than TAF-and was presented within the “TAF-based regimen” arm for efficacy because the efficacy of TAF and TDF are comparable. However the participant was presented separately under “TDF-based regimen” for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early Switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	DTG+3TC FDC (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 milligrams (mg) + 3TC 300 mg once daily up to 148 weeks during early switch phase.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Subject analysis set title	TAF Based Regimen (Early switch)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. One participant randomized to the TAF-based regimen arm received TDF rather than TAF-and was presented within the "TAF-based regimen" arm for efficacy because the efficacy of TAF and TDF are comparable. However, the participant was presented separately under "TDF-based regimen" for Safety because the safety profiles of TDF and TAF differ.

Primary: Percentage of participants with virologic failure endpoint as per Food and Drug Administration (FDA) snapshot category at Week 48

End point title	Percentage of participants with virologic failure endpoint as per Food and Drug Administration (FDA) snapshot category at Week 48

End point description:

Percentage of participants with virologic failure (plasma HIV-1 RNA >=50 c/mL) was evaluated using FDA snapshot algorithm at Week 48. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. Intent-to-treat exposed (ITT-E) Population comprises of all randomized participants who received at least one dose of study treatment either DTG + 3TC or TBR. Participants were assessed according to the treatment to which the participant was randomized. Any participant receiving a treatment randomization number was considered to be randomized. One participant randomized to TBR but received TDF-based regimen and was presented within the “TBR (TAF-based regimen) arm” as efficacy of TAF and TDF are comparable.

End point type	Primary

End point timeframe:

Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[1]	372[2]		
Units: Percentage of participants				
number (not applicable)	0.3	0.5		

Notes:

[1] - ITT-E Population.

[2] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis

Statistical analysis description:

ADP was based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factor:Baseline third agent (protease inhibitor [PI], non-nucleoside reverse transcriptase inhibitor [NNRTI], and integrase inhibitor [INI]).

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	741
Analysis specification	Pre-specified
Analysis type	non-inferiority[3]
Parameter estimate	Adjusted difference in proportion (ADP)
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	0.7

Notes:

[3] - Non-inferiority of switching to DTG + 3TC compared to continuation of TBR (as per FDA snapshot algorithm) was to be concluded if the upper bound of a two-sided 95% confidence interval (CI) for the difference in virologic failure rates between the two treatment arms was smaller than 4%.

Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Week 48

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Week 48

End point description:

Percentage of participants with plasma HIV-1 RNA <50 c/mL (virologic success) was evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG +3TC once daily compared to continuation of TBR over 48 weeks. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Only those participants with data available at specified time points has been analyzed. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	344[4]	346[5]		
Units: Percentage of participants				
number (not applicable)	93.2	93.0		

Notes:

[4] - ITT-E Population.

[5] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

ADP was based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factor: Baseline third agent (PI, NNRTI, and INSTI).

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	690
Analysis specification	Pre-specified
Analysis type	non-inferiority[6]
Parameter estimate	Adjusted difference in proportion
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	3.9

Notes:

[6] - Non-inferiority of switching to DTG + 3TC compared to continuation of TBR (as per FDA snapshot algorithm) was to be concluded when the lower bound of a 2-sided 95% confidence interval for the difference in success rates between the two treatment arms was greater than -8%.

Secondary: Percentage of participants with virologic failure endpoint as per FDA snapshot category at Week 24

End point title	Percentage of participants with virologic failure endpoint as per FDA snapshot category at Week 24

End point description:

Percentage of participants with plasma HIV-1 RNA >=50 c/mL was evaluated using FDA snapshot algorithm at Week 24. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Week 24

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[7]	372[8]		
Units: Percentage of participants				
number (not applicable)	0.3	0.8		

Notes:

[7] - ITT-E Population.

[8] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with virologic failure endpoint as per FDA snapshot category at Weeks 96, 144

End point title	Percentage of participants with virologic failure endpoint as per FDA snapshot category at Weeks 96, 144

End point description:

Percentage of participants with plasma HIV-1 RNA >=50 c/mL was evaluated using FDA snapshot algorithm at Weeks 96 and 144. One participant randomized to TBR but received TDF-based regimen and was presented within the “TBR (TAF-based regimen) arm” as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[9]	372[10]		
Units: Percentage of participants				
number (not applicable)				
Week 96	0.3	1.1		
Week 144	0.3	1.3		

Notes:

[9] - ITT-E Population

[10] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Week 24

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Week 24

End point description:

Percentage of participants with plasma HIV-1 RNA <50 c/mL was evaluated using FDA snapshot algorithm at Week 24. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Only those participants with data available at specified time points has been presented. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable. Percentage values are rounded off.

End point type	Secondary

End point timeframe:

Week 24

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	350[11]	358[12]		
Units: Percentage of participants	95	96		

Notes:

[11] - ITT-E Population.

[12] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Weeks 96 and 144

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Weeks 96 and 144

End point description:

Percentage of participants with plasma HIV-1 RNA <50 c/mL was evaluated using FDA snapshot algorithm at Weeks 96 and 144. Only those participants with data available at specified time points has been analyzed.

End point type	Secondary

End point timeframe:

Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[13]	372[14]		
Units: Percentage of participants				
number (not applicable)				
Week 96	85.9	79.0		
Week 144	85.9	81.7		

Notes:

[13] - ITT-E Population.

[14] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CD4+ cell count at Weeks 24 and 48

End point title	Change from Baseline in CD4+ cell count at Weeks 24 and 48

End point description:

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable. All 741 (369+372) participants were analyzed, however only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[15]	372[16]		
Units: Cells per cubic millimeter				
median (inter-quartile range (Q1-Q3))				
Week 24, n=351, 359	21.0 (-68.0 to 115.0)	6.0 (-87.0 to 99.0)		
Week 48, n=344, 345	22.5 (-71.0 to 121.5)	11.0 (-98.0 to 90.0)		

Notes:

[15] - ITT-E Population.

[16] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CD4+/CD8+ cell count ratio at Weeks 24 and 48

End point title	Change from Baseline in CD4+/CD8+ cell count ratio at Weeks 24 and 48

End point description:

Blood samples were collected at specified time points to assess CD4+/CD8+ cell count ratio. It was assessed by flow cyclometry to evaluate the immunologic activity of switching to DTG+3TC once daily compared to continuation of TBR over 48 Weeks. Baseline (Day 1) values were the actual CD4+ cell count ratio values at pre-dose Day 1. Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable . All 741 (369+372) participants were analyzed, however only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[17]	372[18]		
Units: Ratio				
median (inter-quartile range (Q1-Q3))				
Week 24, n=346, 358	0.010 (-0.070 to 0.110)	0.040 (-0.060 to 0.120)		
Week 48, n=342, 343	0.030 (-0.050 to 0.110)	0.050 (-0.050 to 0.160)		

Notes:

[17] - ITT-E Population.

[18] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CD4+/CD8+ cell count ratio at Weeks 96 and 144

End point title	Change from Baseline in CD4+/CD8+ cell count ratio at Weeks 96 and 144

End point description:

Blood samples were collected at specified time points to assess CD4+/CD8+ cell count ratio and were evaluated by flow cyclometry to evaluate the immunologic activity of switching to DTG+3TC once daily compared to continuation of TBR over Weeks 96 and 144. Baseline (Day 1) values are the actual CD4+ cell count ratio values at pre-dose Day 1. Change from Baseline is defined as post-dose visit value minus Baseline value. All 741 (369+372) participants were analyzed, however only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[19]	372[20]		
Units: Ratio				
median (inter-quartile range (Q1-Q3))				
Week 96, n=312, 292	0.035 (-0.085 to 0.140)	0.080 (-0.050 to 0.170)		
Week 144, n=307, 300	0.060 (-0.060 to 0.200)	0.100 (-0.020 to 0.240)		

Notes:

[19] - ITT-E Population.

[20] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in CD4+ cell count at Weeks 96 and 144

End point title	Change from Baseline in CD4+ cell count at Weeks 96 and 144

End point description:

CD4+ cells are a type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+and evaluated by flow cytometry. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. All 741 (369+372) participants were analyzed, however only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[21]	372[22]		
Units: Cells per cubic millimeter				
median (inter-quartile range (Q1-Q3))				
Week 96, n=315, 295	61.0 (-61.0 to 179.0)	45.0 (-80.0 to 154.0)		
Week 144, n=309, 301	36.0 (-64.0 to 154.0)	35.0 (-60.0 to 134.0)		

Notes:

[21] - ITT-E Population.

[22] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with disease progression at Weeks 24 and 48

End point title	Number of participants with disease progression at Weeks 24 and 48

End point description:

HIV-associated conditions were recorded during the study and were assessed according to the 2014 CDC Classification System for HIV Infection in Adults. CDC classification for HIV were: Stage 1: No AIDS defining condition and CD4+ T-lymphocyte count: >=500 cells/mcL; Stage 2: No AIDS infection and CD4+ lymphocyte count: 200-499 cell/mcL and Stage 3:Documented AIDS defining condition or CD4+ T-lymphocye count <200 cells/mcL. Disease progression summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrollment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrollment to Death. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable

End point type	Secondary

End point timeframe:

At Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[23]	372[24]		
Units: Participants				
From CDC Stage 1 to CDC Stage 3 Event	1	0		
From CDC Stage 2 to CDC Stage 3 Event	0	0		
From CDC Stage 3 to new CDC Stage 3 Event	0	0		
From CDC Stage 1, 2 or 3 to Death	1	0		
No HIV-1 disease progression	367	372		

Notes:

[23] - ITT-E Population.

[24] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with disease progression at Weeks 96 and 144

End point title	Number of participants with disease progression at Weeks 96 and 144

End point description:

HIV-associated conditions were recorded during the study and assessed according to the 2014 CDC Classification System for HIV Infection in Adults. CDC classification for HIV is: Stage 1: No AIDS defining condition and CD4+ T-lymphocyte count: >=500 cells/mcL; Stage 2: No AIDS infection and CD4+ lymphocyte count: 200-499 cell/mcL and Stage 3: Documented AIDS-defining condition or CD4+ T-lymphocye count <200 cells/mcL. Indicators of clinical disease progression is defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrollment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrollment to Death. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable

End point type	Secondary

End point timeframe:

At Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[25]	372[26]		
Units: Participants				
Week 96, From CDC Stage 1 to CDC Stage 3 Event	2	0		
Week 96, From CDC Stage 2 to CDC Stage 3 Event	0	0		
Week 96, From CDC Stage 3 to new CDC Stage 3 Event	0	0		
Week 96, From CDC Stage 1, 2 or 3 to Death	2	0		
Week 96, No HIV-1 disease progression	365	372		
Week 144, From CDC Stage 1 to CDC Stage 3 Event	2	0		
Week 144, From CDC Stage 2 to CDC Stage 3 Event	0	1		
Week 144,From CDC Stage 3 to new CDC Stage 3 Event	0	0		
Week 144, From CDC Stage 1, 2 or 3 to Death	3	0		
Week 144, No HIV-1 disease progression	364	371		

Notes:

[25] - ITT-E Population.

[26] - ITT-E Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any serious adverse events (SAEs) and

common (>=2%) non-serious adverse events (non-SAEs): Up to Week 48

End point title	Number of participants with any serious adverse events (SAEs) and common (>=2%) non-serious adverse events (non-SAEs): Up to Week 48

End point description:

An AE is any untoward medical occurrence temporally associated with use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment. Number of participants with any SAE and common (>=2%) non-SAEs are presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[27]	371[28]		
Units: Participants				
Any non-SAE (>=2%)	222	204		
Any SAE	21	16		

Notes:

[27] - Safety Population.

[28] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with AEs by their severity Grades: Up to Week 48

End point title	Number of Participants with AEs by their severity Grades: Up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[29]	371[30]		
Units: Participants				
Grade 1	102	94		
Grade 2	170	177		
Grade 3	19	15		
Grade 4	3	6		
Grade 5	1	0		

Notes:

[29] - Safety Population.

[30] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any SAEs and common (>=2%) non-SAEs: Up to Week 148

End point title	Number of participants with any SAEs and common (>=2%) non-SAEs: Up to Week 148

End point description:

An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen.

End point type	Secondary

End point timeframe:

Up to Week 148

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[31]	371[32]		
Units: Participants				
Any non-SAE (>=2%)	307	304		
Any SAE	57	44		

Notes:

[31] - Safety Population.

[32] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants randomized to TBR arm receiving TDF-based

regimen with any SAEs and common (>=2%) non-SAEs: Up to Week 48

End point title	Number of participants randomized to TBR arm receiving TDF-based regimen with any SAEs and common (>=2%) non-SAEs: Up to Week 48

End point description:

An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment. Number of TDF-based regimen participants with any SAE and common (>=2%) non-SAEs are presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen.Data not collected post week48 as the participant withdrew from the study

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[33]			
Units: Participants				
Any non-SAE (>=2%)	1			
Any SAE	0			

Notes:

[33] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants randomized to TBR arm receiving TDF-based regimen with AEs by their severity Grades: Up to Week 48

End point title	Number of participants randomized to TBR arm receiving TDF-based regimen with AEs by their severity Grades: Up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of TDF-based regimen participants with adverse events by maximum grade have been presented. Safety Population. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."Data not collected post week 48 as the participant withdrew from the study

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[34]			
Units: Participants				
Grade 1	0			
Grade 2	1			
Grade 3	0			
Grade 4	0			
Grade 5	0			

Notes:

[34] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With AEs by Their Severity Grades: Up to Week 144

End point title	Number of Participants With AEs by Their Severity Grades: Up to Week 144

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[35]	371[36]		
Units: Participants				
Grade 1	57	65		
Grade 2	217	208		
Grade 3	50	54		
Grade 4	9	8		
Grade 5	3	0		

Notes:

[35] - Safety Population

[36] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants who discontinued the treatment due to AEs: Up to Week 48

End point title	Number of participants who discontinued the treatment due to AEs: Up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants who discontinued the treatment due to adverse events have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[37]	371[38]		
Units: Participants	13	2		

Notes:

[37] - Safety Population.

[38] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants who discontinued the treatment due to AEs: Up to Week 144

End point title	Number of participants who discontinued the treatment due to AEs: Up to Week 144

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[39]	371[40]		
Units: Participants	23	7		

Notes:

[39] - Safety Population.

[40] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Maximum Post-Baseline emergent hematology toxicities: Up to Week 48

End point title	Number of participants with Maximum Post-Baseline emergent hematology toxicities: Up to Week 48

End point description:

Blood samples were collected up to Week 48 for the analysis of hematology parameters-platelet count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters were evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the hematology parameters have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[41]	371[42]		
Units: Participants				
Hemoglobin, Grade 1	3	0		
Hemoglobin, Grade 2	0	0		
Hemoglobin, Grade 3	0	0		
Hemoglobin, Grade 4	0	0		
Leukocytes, Grade 1	1	1		
Leukocytes, Grade 2	1	0		
Leukocytes, Grade 3	0	0		
Leukocytes, Grade 4	0	0		
Neutrophils, Grade 1	3	4		
Neutrophils, Grade 2	2	4		
Neutrophils, Grade 3	0	0		

Neutrophils, Grade 4	1	0		
Platelets, Grade 1	6	5		
Platelets, Grade 2	1	1		
Platelets, Grade 3	0	0		
Platelets, Grade 4	0	0		

Notes:

[41] - Safety Population.

[42] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants randomized to TBR arm receiving TDF-based regimen who discontinued the treatment due to AEs: Up to Week 48

End point title	Number of participants randomized to TBR arm receiving TDF-based regimen who discontinued the treatment due to AEs: Up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants who discontinued the treatment due to adverse events have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Data not collected post week 48 as the participant withdrew from the study

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[43]			
Units: Participants	0			

Notes:

[43] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants randomized to TBR arm receiving TDF-based regimen with Maximum Post-Baseline emergent hematology toxicities: Up to Week 36

End point title	Number of participants randomized to TBR arm receiving TDF-based regimen with Maximum Post-Baseline emergent hematology toxicities: Up to Week 36

End point description:

Blood samples were collected up to the Week 36 visit for the analysis of hematology parameters-platelet

count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters were evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. Only those TDF-based regimen participants with maximum post-Baseline emergent hematology toxicities in any of the hematology parameters have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."Data not collected post week 36 as the participant withdrew from the study

End point type	Secondary

End point timeframe:

Up to Week 36

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[44]			
Units: Participants				
Hemoglobin, Grade 1	0			
Hemoglobin, Grade 2	0			
Hemoglobin, Grade 3	0			
Hemoglobin, Grade 4	0			
Leukocytes, Grade 1	0			
Leukocytes, Grade 2	0			
Leukocytes, Grade 3	0			
Leukocytes, Grade 4	0			
Neutrophils, Grade 1	0			
Neutrophils, Grade 2	0			
Neutrophils, Grade 3	0			
Neutrophils, Grade 4	0			
Platelets, Grade 1	0			
Platelets, Grade 2	0			
Platelets, Grade 3	0			
Platelets, Grade 4	0			

Notes:

[44] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities: Up to Week 144

End point title	Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities: Up to Week 144

End point description:

Blood samples were collected up to Week 144 for the analysis of hematology parameters-platelet count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters are planned to be evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the

symptoms. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[45]	371[46]		
Units: Participants				
Hemoglobin, Grade 1	7	2		
Hemoglobin, Grade 2	1	2		
Hemoglobin, Grade 3	0	0		
Hemoglobin, Grade 4	0	0		
Leukocytes, Grade 1	2	4		
Leukocytes, Grade 2	1	0		
Leukocytes, Grade 3	1	0		
Leukocytes, Grade 4	0	0		
Neutrophils, Grade 1	5	5		
Neutrophils, Grade 2	3	8		
Neutrophils, Grade 3	0	0		
Neutrophils, Grade 4	2	2		
Platelets, Grade 1	8	7		
Platelets, Grade 2	2	1		
Platelets, Grade 3	0	0		
Platelets, Grade 4	0	0		

Notes:

[45] - Safety Population.

[46] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 48

End point title	Number of participants with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 48

End point description:

Blood samples were collected for analysis of alanine aminotransferase(ALT), albumin, alkaline phosphate(ALP), aspartate aminotransferase(AST), bilirubin, carbon dioxide(CO2), cholesterol, creatinine kinase(CK), creatinine, direct bilirubin, glomerular filtration rate(GFR) from creatinine adjusted for body surface area(BSA), GFR from cystatin C adjusted using chronic kidney disease-epidemiology collaboration(CKD-EPI), hyper/hypocalcemia, hyper/hypo-glycemia, hyper/hypo-kalemia, hyper/hypo-natremia, low density lipoprotein(LDL) cholesterol, phosphate and triglycerides. Any abnormality was evaluated according to DAIDS toxicity scale From Grade1-4 as mild,moderates,severe and Potentially life-threatening. Higher the grade, more severe the symptoms. 1 participant randomized to TBR but received TDF and because safety profiles of TDF and TAF differ, this participant was removed from overall safety population and presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary
End point timeframe:	
Up to Week 48	

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[47]	371[48]		
Units: Participants				
ALT, Grade 1	24	18		
ALT, Grade 2	6	4		
ALT, Grade 3	1	1		
ALT, Grade 4	0	0		
Albumin, Grade 1	1	0		
Albumin, Grade 2	0	0		
Albumin, Grade 3	0	0		
Albumin, Grade 4	0	0		
ALP, Grade 1	2	0		
ALP, Grade 2	0	0		
ALP, Grade 3	0	0		
ALP, Grade 4	0	0		
AST, Grade 1	21	29		
AST, Grade 2	7	4		
AST, Grade 3	1	0		
AST, Grade 4	1	0		
Bilirubin, Grade 1	17	7		
Bilirubin, Grade 2	5	2		
Bilirubin, Grade 3	1	1		
Bilirubin, Grade 4	0	0		
CO2, Grade 1	73	70		
CO2, Grade 2	1	1		
CO2, Grade 3	0	0		
CO2, Grade 4	0	0		
Cholesterol, Grade 1	27	52		
Cholesterol, Grade 2	12	19		
Cholesterol, Grade 3	1	0		
Cholesterol, Grade 4	0	0		
CK, Grade 1	28	19		
CK, Grade 2	4	9		
CK, Grade 3	9	8		
CK, Grade 4	6	5		
Creatinine, Grade 1	16	7		
Creatinine, Grade 2	3	1		
Creatinine, Grade 3	0	0		
Creatinine, Grade 4	0	0		
Direct bilirubin, Grade 1	0	0		
Direct bilirubin, Grade 2	0	0		
Direct bilirubin, Grade 3	8	1		

Direct bilirubin, Grade 4	0	0		
GFR from creatinine adjusted using CKD EPI,Grade 1	0	0		
GFR from creatinine adjusted using CKD EPI,Grade 2	135	83		
GFR from creatinine adjusted using CKD EPI,Grade 3	26	13		
GFR from creatinine adjusted using CKD EPI,Grade 4	0	0		
GFR from cystatin C adjusted using CKD-EPI,Grade 1	0	0		
GFR from cystatin C adjusted using CKD-EPI,Grade 2	52	66		
GFR from cystatin C adjusted using CKD-EPI,Grade 3	5	4		
GFR from cystatin C adjusted using CKD-EPI,Grade 4	1	0		
Hypercalcemia, Grade 1	7	3		
Hypercalcemia, Grade 2	0	0		
Hypercalcemia, Grade 3	0	0		
Hypercalcemia, Grade 4	0	0		
Hyperglycemia, Grade 1	56	64		
Hyperglycemia, Grade 2	21	19		
Hyperglycemia, Grade 3	2	2		
Hyperglycemia, Grade 4	0	0		
Hyperkalemia, Grade 1	0	2		
Hyperkalemia, Grade 2	2	0		
Hyperkalemia, Grade 3	0	0		
Hyperkalemia, Grade 4	0	0		
Hypernatremia, Grade 1	1	1		
Hypernatremia, Grade 2	0	0		
Hypernatremia, Grade 3	0	0		
Hypernatremia, Grade 4	0	0		
Hypocalcemia, Grade 1	8	1		
Hypocalcemia, Grade 2	0	1		
Hypocalcemia, Grade 3	0	0		
Hypocalcemia, Grade 4	0	0		
Hypoglycemia, Grade 1	5	6		
Hypoglycemia, Grade 2	3	2		
Hypoglycemia, Grade 3	0	0		
Hypoglycemia, Grade 4	0	0		
Hypokalemia, Grade 1	7	1		
Hypokalemia, Grade 2	1	0		
Hypokalemia, Grade 3	0	0		
Hypokalemia, Grade 4	0	0		
Hyponatremia, Grade 1	8	13		
Hyponatremia, Grade 2	0	2		
Hyponatremia, Grade 3	0	0		
Hyponatremia, Grade 4	0	0		
LDL cholesterol, Grade 1	28	35		
LDL cholesterol, Grade 2	13	15		
LDL cholesterol, Grade 3	6	3		
LDL cholesterol, Grade 4	0	0		
Phosphate, Grade 1	38	47		

Phosphate, Grade 2	2	7		
Phosphate, Grade 3	0	0		
Phosphate, Grade 4	0	0		
Triglycerides, Grade 1	34	48		
Triglycerides, Grade 2	4	11		
Triglycerides, Grade 3	4	4		
Triglycerides, Grade 4	4	0		

Notes:

[47] - Safety Population.

[48] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants randomized to TBR arm receiving TDF-based regimen with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 36

End point title	Number of participants randomized to TBR arm receiving TDF-based regimen with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 36

End point description:

Blood samples were collected up to Week 36 visit for analysis of clinical chemistry parameters:ALT, albumin,ALP,AST,bilirubin,CO2,cholesterol,CK,creatinine,direct bilirubin,GFR from creatinine adjusted for BSA, GFR from cystatin C adjusted using CKD-EPI, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, LDL cholesterol, phosphate& triglycerides. Any abnormality in clinical chemistry parameters were evaluated according to DAIDS toxicity scale From Grade 1 to 4:Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe),Grade 4 (Potentially life-threatening). Higher the grade, more severe the symptoms. One participant randomized to TBR but received TDF-based regimen & because safety profiles of TDF&TAF differ, this participant was removed from overall safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen." Data not collected post week 36 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Up to Week 36

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[49]			
Units: Participants				
ALT, Grade 1	0			
ALT, Grade 2	0			
ALT, Grade 3	0			
ALT, Grade 4	0			
Albumin, Grade 1	0			
Albumin, Grade 2	0			
Albumin, Grade 3	0			
Albumin, Grade 4	0			
ALP, Grade 1	0			

ALP, Grade 2	0			
ALP, Grade 3	0			
ALP, Grade 4	0			
AST, Grade 1	0			
AST, Grade 2	0			
AST, Grade 3	0			
AST, Grade 4	0			
Bilirubin, Grade 1	0			
Bilirubin, Grade 2	0			
Bilirubin, Grade 3	0			
Bilirubin, Grade 4	0			
CO2, Grade 1	0			
CO2, Grade 2	0			
CO2, Grade 3	0			
CO2, Grade 4	0			
Cholesterol, Grade 1	0			
Cholesterol, Grade 2	0			
Cholesterol, Grade 3	0			
Cholesterol, Grade 4	0			
CK, Grade 1	0			
CK, Grade 2	0			
CK, Grade 3	0			
CK, Grade 4	0			
Creatinine, Grade 1	0			
Creatinine, Grade 2	0			
Creatinine, Grade 3	0			
Creatinine, Grade 4	0			
Direct bilirubin, Grade 1	0			
Direct bilirubin, Grade 2	0			
Direct bilirubin, Grade 3	0			
Direct bilirubin, Grade 4	0			
GFR from creatinine adjusted using CKD EPI,Grade 1	0			
GFR from creatinine adjusted using CKD EPI,Grade 2	0			
GFR from creatinine adjusted using CKD EPI,Grade 3	0			
GFR from creatinine adjusted using CKD EPI,Grade 4	0			
GFR from cystatin C adjusted using CKD-EPI,Grade 1	0			
GFR from cystatin C adjusted using CKD-EPI,Grade 2	0			
GFR from cystatin C adjusted using CKD-EPI,Grade 3	0			
GFR from cystatin C adjusted using CKD-EPI,Grade 4	0			
Hypercalcemia, Grade 1	0			
Hypercalcemia, Grade 2	0			
Hypercalcemia, Grade 3	0			
Hypercalcemia, Grade 4	0			
Hyperglycemia, Grade 1	0			
Hyperglycemia, Grade 2	0			
Hyperglycemia, Grade 3	0			

Hyperglycemia, Grade 4	0			
Hyperkalemia, Grade 1	0			
Hyperkalemia, Grade 2	0			
Hyperkalemia, Grade 3	0			
Hyperkalemia, Grade 4	0			
Hypernatremia, Grade 1	0			
Hypernatremia, Grade 2	0			
Hypernatremia, Grade 3	0			
Hypernatremia, Grade 4	0			
Hypocalcemia, Grade 1	0			
Hypocalcemia, Grade 2	0			
Hypocalcemia, Grade 3	0			
Hypocalcemia, Grade 4	0			
Hypoglycemia, Grade 1	0			
Hypoglycemia, Grade 2	0			
Hypoglycemia, Grade 3	0			
Hypoglycemia, Grade 4	0			
Hypokalemia, Grade 1	0			
Hypokalemia, Grade 2	0			
Hypokalemia, Grade 3	0			
Hypokalemia, Grade 4	0			
Hyponatremia, Grade 1	0			
Hyponatremia, Grade 2	0			
Hyponatremia, Grade 3	0			
Hyponatremia, Grade 4	0			
LDL cholesterol, Grade 1	0			
LDL cholesterol, Grade 2	0			
LDL cholesterol, Grade 3	0			
LDL cholesterol, Grade 4	0			
Phosphate, Grade 1	0			
Phosphate, Grade 2	0			
Phosphate, Grade 3	0			
Phosphate, Grade 4	0			
Triglycerides, Grade 1	1			
Triglycerides, Grade 2	0			
Triglycerides, Grade 3	0			
Triglycerides, Grade 4	0			

Notes:

[49] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 144

End point title	Number of participants with Maximum Post-Baseline emergent clinical chemistry toxicities: Up to Week 144

End point description:

Blood samples were collected up to Week 144 for the analysis of clinical chemistry parameters: ALT, albumin, ALP, AST, bilirubin, CO2, cholesterol, CK, creatinine, direct bilirubin, GFR from creatinine adjusted for BSA, GFR from cystatin C adjusted using CKD-EPI, hypercalcemia, hyperglycemia,

hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, LDL cholesterol, phosphate triglycerides and lactate dehydrogenase. Any abnormality in clinical chemistry parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms.One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[50]	371[51]		
Units: Participants				
ALT, Grade 1	55	49		
ALT, Grade 2	11	9		
ALT, Grade 3	5	3		
ALT, Grade 4	0	1		
Albumin, Grade 1	1	0		
Albumin, Grade 2	2	0		
Albumin, Grade 3	0	0		
Albumin, Grade 4	0	0		
ALP, Grade 1	6	0		
ALP, Grade 2	0	0		
ALP, Grade 3	0	1		
ALP, Grade 4	0	0		
AST, Grade 1	34	45		
AST, Grade 2	13	9		
AST, Grade 3	3	0		
AST, Grade 4	3	3		
Bilirubin, Grade 1	24	12		
Bilirubin, Grade 2	9	4		
Bilirubin, Grade 3	3	1		
Bilirubin, Grade 4	0	0		
CO2, Grade 1	110	97		
CO2, Grade 2	2	4		
CO2, Grade 3	1	0		
CO2, Grade 4	0	0		
Cholesterol, Grade 1	42	70		
Cholesterol, Grade 2	26	34		
Cholesterol, Grade 3	1	2		
Cholesterol, Grade 4	0	0		
CK, Grade 1	41	30		
CK, Grade 2	12	13		
CK, Grade 3	12	12		
CK, Grade 4	10	10		
Creatinine, Grade 1	21	12		
Creatinine, Grade 2	5	2		

Creatinine, Grade 3	1	1		
Creatinine, Grade 4	0	0		
Direct bilirubin, Grade 1	0	0		
Direct bilirubin, Grade 2	0	0		
Direct bilirubin, Grade 3	13	3		
Direct bilirubin, Grade 4	0	0		
GFR from creatinine adjusted using CKD EPI,Grade 1	0	0		
GFR from creatinine adjusted using CKD EPI,Grade 2	165	101		
GFR from creatinine adjusted using CKD EPI,Grade 3	38	24		
GFR from creatinine adjusted using CKD EPI,Grade 4	0	1		
GFR from cystatin C adjusted using CKD-EPI,Grade 1	0	0		
GFR from cystatin C adjusted using CKD-EPI,Grade 2	169	183		
GFR from cystatin C adjusted using CKD-EPI,Grade 3	46	58		
GFR from cystatin C adjusted using CKD-EPI,Grade 4	1	1		
Hypercalcemia, Grade 1	8	9		
Hypercalcemia, Grade 2	0	0		
Hypercalcemia, Grade 3	0	0		
Hypercalcemia, Grade 4	0	0		
Hyperglycemia, Grade 1	73	77		
Hyperglycemia, Grade 2	40	31		
Hyperglycemia, Grade 3	4	4		
Hyperglycemia, Grade 4	0	0		
Hyperkalemia, Grade 1	3	2		
Hyperkalemia, Grade 2	2	1		
Hyperkalemia, Grade 3	0	0		
Hyperkalemia, Grade 4	0	0		
Hypernatremia, Grade 1	4	3		
Hypernatremia, Grade 2	1	0		
Hypernatremia, Grade 3	0	0		
Hypernatremia, Grade 4	0	0		
Hypocalcemia, Grade 1	14	5		
Hypocalcemia, Grade 2	1	2		
Hypocalcemia, Grade 3	0	0		
Hypocalcemia, Grade 4	0	0		
Hypoglycemia, Grade 1	9	10		
Hypoglycemia, Grade 2	4	3		
Hypoglycemia, Grade 3	0	0		
Hypoglycemia, Grade 4	0	0		
Hypokalemia, Grade 1	10	7		
Hypokalemia, Grade 2	3	0		
Hypokalemia, Grade 3	1	0		
Hypokalemia, Grade 4	0	0		
Hyponatremia, Grade 1	21	26		
Hyponatremia, Grade 2	0	2		
Hyponatremia, Grade 3	0	0		
Hyponatremia, Grade 4	0	0		

LDL cholesterol, Grade 1	41	56		
LDL cholesterol, Grade 2	19	24		
LDL cholesterol, Grade 3	8	9		
LDL cholesterol, Grade 4	0	0		
Phosphate, Grade 1	61	71		
Phosphate, Grade 2	3	9		
Phosphate, Grade 3	0	0		
Phosphate, Grade 4	0	0		
Triglycerides, Grade 1	60	77		
Triglycerides, Grade 2	6	15		
Triglycerides, Grade 3	6	5		
Triglycerides, Grade 4	4	2		
Lactate Dehydrogenase Grade 1	0	1		
Lactate Dehydrogenase Grade 2	0	0		
Lactate Dehydrogenase Grade 3	0	0		
Lactate Dehydrogenase Grade 4	0	0		

Notes:

[50] - Safety Population.

[51] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers- Urine albumin/creatinine (UA/C) ratio and Urine protein/creatinine (UP/C) ratio at Weeks 24 and 48

End point title	Change from Baseline in renal biomarkers- Urine albumin/creatinine (UA/C) ratio and Urine protein/creatinine (UP/C) ratio at Weeks 24 and 48

End point description:

Baseline is defined as Day 1. Change from Baseline in UA/C was calculated as UA/C ratio at post-Baseline visit minus UA/C ratio calculated at Baseline. Change from Baseline in UP/C and UA/C was calculated as UP/C and UA/C ratio at post-Baseline visit minus UP/C and UA/C ratio calculated at Baseline, respectively. Estimated geometric mean adjusted ratio and 95% CI have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen. Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Participants with data available at specified data points were analyzed (represented by n= X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[52]	371[53]		
Units: Ratio				
geometric mean (confidence interval 95%)				

UA/C, Week 24, n=235, 230	1.080 (1.007 to 1.158)	1.022 (0.956 to 1.091)		
UA/C, Week 48, n=230, 224	1.125 (1.036 to 1.222)	1.059 (0.963 to 1.165)		
UP/C, Week 24, n=267, 261	0.955 (0.917 to 0.995)	0.976 (0.937 to 1.016)		
UP/C, Week 48, n=261, 257	0.971 (0.926 to 1.018)	1.016 (0.964 to 1.070)		

Notes:

[52] - Safety Population.

[53] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UA/C at Week 24 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.257
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.057
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.96
upper limit	1.164

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UA/C at Week 48 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.35
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.062
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.936
upper limit	1.205

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UP/C at Week 24 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.473
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.979
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.924
upper limit	1.037

Statistical analysis title	Statistical Analysis 4
Statistical analysis description: Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UP/C at Week 48 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.212
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.956
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.891
upper limit	1.026

Secondary: Change from Baseline in renal biomarkers- UA/C ratio and UP/C ratio at Weeks 24 and 48 in participants randomized to TBR receiving TDF-based regimen

End point title	Change from Baseline in renal biomarkers- UA/C ratio and UP/C ratio at Weeks 24 and 48 in participants randomized to TBR receiving TDF-based regimen

End point description:

Urine samples were collected at Baseline, Week 24 and Week 48 to assess renal biomarkers - urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline was defined as the latest pre-dose assessment value (Day 1) with a non-missing value. Change from Baseline in UP/C and UA/C was

calculated as UP/C and UA/C ratio at post-Baseline visit minus UP/C and UA/C ratio calculated at Baseline, respectively. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. Data not collected post week 48 as the participant withdrew from the study

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[54]			
Units: Ratio				
number (not applicable)				
UA/C, Week 24, n=1	0			
UA/C, Week 48, n=0	99999			
UP/C, Week 24, n=1	0.3			
UP/C, Week 48, n=0	99999			

Notes:

[54] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers- UA/C ratio and UP/C ratio at Weeks 96 and 144

End point title	Change from Baseline in renal biomarkers- UA/C ratio and UP/C ratio at Weeks 96 and 144

End point description:

Baseline is defined as Day 1. Change from Baseline in UA/C was calculated as UA/C ratio at post-Baseline visit minus UA/C ratio calculated at Baseline. Change from Baseline in UP/C and UA/C was calculated as UP/C and UA/C ratio at post-Baseline visit minus UP/C and UA/C ratio calculated at Baseline, respectively. Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Participants with data available at specified data points were analyzed (represented by n= X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[55]	371[56]		
Units: Ratio				
geometric mean (confidence interval 95%)				
UA/C, Week 96, n=208, 175	1.058 (0.974 to 1.149)	1.075 (0.968 to 1.195)		
UA/C, Week 144, n=202, 179	1.203 (1.093 to 1.324)	1.200 (1.051 to 1.371)		
UP/C, Week 96, n=245, 206	1.048 (0.997 to 1.102)	1.105 (1.044 to 1.169)		
UP/C, Week 144, n=237, 220	1.182 (1.121 to 1.247)	1.188 (1.104 to 1.278)		

Notes:

[55] - Safety Population.

[56] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UA/C at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.977
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.866
upper limit	1.102

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UP/C at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.814
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.991

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.916
upper limit	1.071

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UP/C at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.356
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.969
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.907
upper limit	1.036

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for UA/C at Week 144 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.971
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.835
upper limit	1.129

Secondary: Change from Baseline in renal biomarkers- Urine beta-2 microglobulin/urine creatinine ratio at Weeks 24 and 48

End point title	Change from Baseline in renal biomarkers- Urine beta-2

	microglobulin/urine creatinine ratio at Weeks 24 and 48

End point description:

Geometric mean ratio (visit/Baseline) and 95% CI of geometric mean ratio has been presented. Baseline was defined as Day 1. Change from Baseline in urine beta-2-microglobulin/urine creatinine was calculated as urine beta-2-microglobulin/urine creatinine ratio at post-Baseline visit minus urine beta-2-microglobulin/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at specified data points were analyzed (represented by n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[57]	371[58]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Week 24, n=136, 141	0.991 (0.899 to 1.093)	1.034 (0.931 to 1.149)		
Week 48, n=126, 141	0.973 (0.870 to 1.088)	0.922 (0.832 to 1.022)		

Notes:

[57] - Safety Population.

[58] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine beta-2 microglobulin/urine creatinine at Week 48 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.489
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.055
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.906
upper limit	1.229

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine beta-2 microglobulin/urine creatinine at Week 24 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.56
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.958
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.106

Secondary: Change from Baseline in renal biomarkers- Urine phosphate at Weeks 24 and 48

End point title	Change from Baseline in renal biomarkers- Urine phosphate at Weeks 24 and 48

End point description:

Urine biomarker samples were collected at Baseline and at Weeks 24 and 48 to assess urine phosphate. Geometric mean ratio (visit divided by Baseline) and 95% CI of geometric mean ratio has been presented. Baseline was defined as Day 1. Change from Baseline in urine phosphate was calculated as urine phosphate at post-Baseline visit minus urine phosphate calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[59]	371[60]		
Units: Ratio				
geometric mean (confidence interval 95%)				

Week 24, n=348, 352	0.955 (0.888 to 1.028)	0.940 (0.871 to 1.014)		
Week 48, n=342, 340	0.969 (0.892 to 1.052)	0.970 (0.900 to 1.044)		

Notes:

[59] - Safety Population.

[60] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine phosphate at Week 48 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.985
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.999
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.894
upper limit	1.116

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine phosphate at Week 24 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.758
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.017
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.915
upper limit	1.13

Secondary: Change from Baseline in renal biomarkers- Urine beta-2

microglobulin/urine creatinine ratio at Weeks 96 and 144	
End point title	Change from Baseline in renal biomarkers- Urine beta-2 microglobulin/urine creatinine ratio at Weeks 96 and 144

End point description:

Geometric mean ratio (visit/Baseline) and 95% CI of geometric mean ratio has been presented. Baseline was defined as Day 1. Change from Baseline in urine beta-2-microglobulin/urine creatinine was calculated as urine beta-2-microglobulin/urine creatinine ratio at post-Baseline visit minus urine beta-2-microglobulin/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at specified data points were analyzed (represented by n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[61]	371[62]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Week 96, n=109, 107	1.080 (0.931 to 1.253)	0.986 (0.844 to 1.152)		
Week 144, n=101, 97	0.904 (0.768 to 1.065)	0.958 (0.808 to 1.136)		

Notes:

[61] - Safety Population.

[62] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine beta-2 microglobulin/urine creatinine at Week 144 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.834
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.981
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.819
upper limit	1.175

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine beta-2 microglobulin/urine creatinine at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.081
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.165
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.981
upper limit	1.384

Secondary: Change from Baseline in renal biomarkers- Urine phosphate at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in renal biomarkers- Urine phosphate at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Urine biomarker samples were collected to assess urine phosphate. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine phosphate was calculated as urine phosphate at post-Baseline visit minus urine phosphate calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."99999 indicates data is not available. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[63]			
Units: Ratio				
number (not applicable)				

Week 24, n=1 Week 48, n=0	2.9 99999			

Notes:

[63] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers- Urine phosphate at Weeks 96 and 144

End point title	Change from Baseline in renal biomarkers- Urine phosphate at Weeks 96 and 144

End point description:

Urine biomarker samples were collected at Baseline, Weeks 96 and 144 to assess urine phosphate. Geometric mean ratio (visit divided by Baseline) and 95% CI of geometric mean ratio has been presented. Baseline was defined as Day 1. Change from Baseline in urine phosphate was calculated as urine phosphate at post-Baseline visit minus urine phosphate calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[64]	371[65]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Week 96, n=312, 286	0.960 (0.871 to 1.057)	0.978 (0.882 to 1.085)		
Week 144, n=313, 298	0.890 (0.805 to 0.985)	0.912 (0.825 to 1.007)		

Notes:

[64] - Safety Population.

[65] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine phosphate at Week 144 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.745
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.019
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.909
upper limit	1.142

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine phosphate at Week 96 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.806
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.015
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.904
upper limit	1.139

Secondary: Change from Baseline in renal biomarkers- Urine retinol binding protein 4/urine creatinine at weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in renal biomarkers- Urine retinol binding protein 4/urine creatinine at weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Urine biomarker samples were collected to assess urine retinol binding protein 4/urine creatinine.Baseline (Day 1) value was the value from the latest pre-dose assessment with non-missing value, including those from unscheduled visits.Change from Baseline in urine retinol binding protein 4/urine creatinine was calculated as urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus urine retinol binding protein 4/urine creatinine ratio calculated at Baseline.One participant randomized to TBR but received TDF-based regimen & because the safety profiles of TDF & TAF differ, participant was removed from the overall safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen." 99999 indicates data is not available. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[66]			
Units: Ratio				
number (not applicable)				
Week 24, n=1	1.04			
Week 48, n=0	99999			

Notes:

[66] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarkers- Urine retinol binding protein 4/urine creatinine at Weeks 24 and 48

End point title	Change from Baseline in renal biomarkers- Urine retinol binding protein 4/urine creatinine at Weeks 24 and 48

End point description:

Geometric mean ratio (visit/Baseline) and 95% CI of geometric mean ratio has been presented. Baseline is defined as Day 1. Change from Baseline in Urine retinol binding protein 4/urine creatinine ratio was calculated as Urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus Urine retinol binding protein 4/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at specified data points were analyzed (represented by n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[67]	371[68]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Week 24, n=344, 343	0.860 (0.790 to 0.936)	0.920 (0.847 to 0.999)		

Week 48, n=340, 335	1.063 (0.992 to 1.139)	1.068 (0.996 to 1.144)		

Notes:

[67] - Safety Population.

[68] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine retinol binding protein 4/urine creatinine at Week 48 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.932
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	0.996
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.903
upper limit	1.098

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine retinol binding protein 4/urine creatinine at Week 24 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.264
Method	Mixed Model Reported Measures
Parameter estimate	Treatment ratio
Point estimate	0.935
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.052

Secondary: Change from Baseline in renal biomarkers- Urine retinol binding protein

4/urine creatinine at Weeks 96 and 144

End point title	Change from Baseline in renal biomarkers- Urine retinol binding protein 4/urine creatinine at Weeks 96 and 144

End point description:

Geometric mean ratio (visit/Baseline) and 95% CI of geometric mean ratio has been presented. Baseline is defined as Day 1. Change from Baseline in Urine retinol binding protein 4/urine creatinine ratio was calculated as Urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus Urine retinol binding protein 4/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at specified data points were analyzed (represented by n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[69]	371[70]		
Units: Ratio				
geometric mean (confidence interval 95%)				
Week 96, n=310, 282	0.926 (0.845 to 1.014)	0.851 (0.775 to 0.933)		
Week 144, n=304, 288	1.188 (1.086 to 1.298)	1.227 (1.109 to 1.359)		

Notes:

[69] - Safety Population.

[70] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine retinol binding protein 4/urine creatinine at Week 144 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.895
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.007
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.905
upper limit	1.121

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Treatment ratio (DTG+3TC/ TAF based regimen) and 95% CI for Urine retinol binding protein 4/urine creatinine at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.011
Method	Mixed Model Repeated Measures
Parameter estimate	Treatment ratio
Point estimate	1.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.032
upper limit	1.281

Secondary: Change from Baseline in fasting lipids at Weeks 24 and 48

End point title	Change from Baseline in fasting lipids at Weeks 24 and 48

End point description:

Blood samples were collected at Baseline (Day 1), Week 24 and Week 48 to assess fasting lipids which included plasma cholesterol, plasma LDL cholesterol, plasma high density lipoprotein (HDL) cholesterol and plasma triglycerides. Baseline value was the value from the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Safety Population. Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[71]	371[72]		
Units: Millimoles per liter				
median (inter-quartile range (Q1-Q3))				
Plasma cholesterol, Week 24, n=282, 264	-0.325 (-0.750 to 0.150)	0.000 (-0.400 to 0.400)		
Plasma cholesterol, Week 48, n=275, 263	-0.200 (-0.750 to 0.150)	0.100 (-0.350 to 0.500)		

Plasma LDL Cholesterol, Week 24, n=282, 264	-0.210 (-0.570 to 0.130)	-0.060 (-0.340 to 0.410)		
Plasma LDL Cholesterol, Week 48, n=275, 263	-0.170 (-0.560 to 0.210)	0.070 (-0.320 to 0.430)		
Plasma Triglycerides, Week 24, n=282, 264	-0.100 (-0.460 to 0.160)	0.060 (-0.200 to 0.350)		
Plasma Triglycerides, Week 48, n=275, 263	-0.100 (-0.440 to 0.160)	0.100 (-0.280 to 0.380)		
Plasma HDL Cholesterol, Week 24, n=282, 264	-0.050 (-0.150 to 0.100)	0.050 (-0.150 to 0.150)		
Plasma HDL Cholesterol, Week 48, n=275, 263	0.000 (-0.200 to 0.150)	0.050 (-0.150 to 0.150)		

Notes:

[71] - Safety Population.

[72] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in fasting lipids at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in fasting lipids at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Blood samples were collected (participant withdrew from the study at Week 36) to assess fasting lipids which included plasma cholesterol, plasma LDL cholesterol, plasma HDL cholesterol & plasma triglycerides. Baseline value was the value from latest pre-dose assessment with non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for fasting lipids in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen & because the safety profiles of TDF & TAF differ,participant was removed from the overall safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen." 99999 indicates data is not available.Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[73]			
Units: Millimoles per liter				
number (not applicable)				
Plasma cholesterol, Week 24, n=1	0			
Plasma cholesterol, Week 48, n=0	99999			
Plasma LDL Cholesterol, Week 24, n=1	-0.67			
Plasma LDL Cholesterol, Week 48, n=0	99999			
Plasma Triglycerides, Week 24, n=1	1.36			
Plasma Triglycerides, Week 48, n=0	99999			

Plasma HDL Cholesterol, Week 24, n=1	0.05			
Plasma HDL Cholesterol, Week 48, n=0	99999			

Notes:

[73] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in fasting lipids at Weeks 96 and 144

End point title	Change from Baseline in fasting lipids at Weeks 96 and 144

End point description:

Blood samples were collected at Baseline (Day 1), Weeks 96 and 144 to assess fasting lipids which included plasma cholesterol, plasma LDL cholesterol, plasma high density lipoprotein (HDL) cholesterol and plasma triglycerides. Baseline value was the value from the latest pre-dose assessment (Day 1) with a non-missing value. Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[74]	371[75]		
Units: Millimoles per liter				
median (inter-quartile range (Q1-Q3))				
Plasma cholesterol, Week 96, n=238, 213	-3.7 (-12.4 to 5.6)	1.2 (-6.0 to 10.6)		
Plasma cholesterol, Week 144, n=243, 230	-4.0 (-13.0 to 6.4)	3.8 (-5.0 to 14.5)		
Plasma LDL Cholesterol, Week 96, n=238, 213	-5.6 (-17.3 to 10.8)	1.7 (-8.9 to 15.8)		
Plasma LDL Cholesterol, Week 144, n=243, 230	-5.0 (-16.2 to 10.7)	4.2 (-9.0 to 20.9)		
Plasma Triglycerides, Week 96, n=238, 213	-2.1 (-25.8 to 22.2)	4.9 (-20.0 to 38.9)		
Plasma Triglycerides, Week 144, n=243, 230	-9.4 (-32.8 to 21.2)	2.2 (-23.0 to 30.3)		
Plasma HDL Cholesterol, Week 96, n=238, 213	-3.8 (-13.8 to 8.5)	0.0 (-10.8 to 13.0)		
Plasma HDL Cholesterol, Week 144, n=243, 230	-3.8 (-14.3 to 12.0)	3.8 (-8.0 to 17.4)		

Notes:

[74] - Safety Population.

[75] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with genotypic resistance: Up to Week 48

End point title	Number of participants with genotypic resistance: Up to Week 48

End point description:

Plasma samples were collected for drug resistance testing. Number of participants, who met confirmed virologic withdrawal (CVW) criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with emergent genotypic resistance to INSTI, nucleoside reverse transcriptase inhibitor (NRTI), NNRTI and PI was summarized. CVW Population comprises all participants in the ITT-E Population who had met the derived CVW criteria. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	TAF Based Regimen (Early switch)			
Subject group type	Subject analysis set			
Number of subjects analysed	1[76]			
Units: Participants				
INSTI	0			
NRTI	0			
NNRTI	0			
PI	0			

Notes:

[76] - CVW Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with genotypic resistance: Up to Week 144

End point title	Number of participants with genotypic resistance: Up to Week 144

End point description:

Plasma samples were collected for drug resistance testing. Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with genotypic resistance to INSTI, NRTI, NNRTI and PI are summarized. CVW Population comprises all participants in the ITT-E Population who had met the derived CVW criteria and who had resistance data. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Up to Week 144

End point values	TAF Based Regimen (Early Switch)			
Subject group type	Subject analysis set			
Number of subjects analysed	2[77]			
Units: Participants				
INSTI	0			
NRTI	0			
NNRTI	0			
PI	0			

Notes:

[77] - CVW Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with phenotypic resistance: Up to Week 48

End point title	Number of participants with phenotypic resistance: Up to Week 48

End point description:

Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with phenotypic resistance to INSTI, NNRTI,NRTI and PI were summarized. Assessment of antiviral activity of ART using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences), which provided the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The phenotypic resistance was calculated using binary scoring system, where 0 was considered as sensitive and 1 as resistance. Phenotypic Resistance data for the following INSTI, NNRTI, NRTI and PI drugs in participants Meeting CVW Criteria has been presented. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	TAF Based Regimen (Early switch)			
Subject group type	Subject analysis set			
Number of subjects analysed	1[78]			
Units: Participants				
INSTI, DTG, Sensitive	1			
INSTI, DTG, Resistant	0			
INSTI, Bictegravir (BIC), Sensitive	1			
INSTI, BIC, Resistant	0			
INSTI, Elvitegravir (EVG), Sensitive	1			
INSTI, EVG, Resistant	0			
INSTI, Raltegravir (RAL), Sensitive	1			
INSTI, RAL, Resistant	0			
NNRTI, Delavirdine (DLV), Sensitive	1			
NNRTI, DLV, Resistant	0			
NNRTI, Efavirenz (EFV), Sensitive	1			

NNRTI, EFV, Resistant	0			
NNRTI, Etravirine (ETR), Sensitive	1			
NNRTI, ETR, Resistant	0			
NNRTI, Nevirapine (NVP), Sensitive	1			
NNRTI, NVP, Resistant	0			
NNRTI, Rilpivirine (RPV), Sensitive	1			
NNRTI, RPV, Resistant	0			
NRTI, 3TC, Sensitive	1			
NRTI, 3TC, Resistant	0			
NRTI, Abacavir (ABC), Sensitive	1			
NRTI, ABC, Resistant	0			
NRTI, Zidovudine (AZT), Sensitive	1			
NRTI, AZT, Resistant	0			
NRTI, Stavudine (D4T), Sensitive	1			
NRTI, D4T, Resistant	0			
NRTI, Didanosine (DDI), Sensitive	1			
NRTI, DDI, Resistant	0			
NRTI, Emtricitabine (FTC), Sensitive	1			
NRTI, FTC, Resistant	0			
NRTI, Tenofovir (TDF), Sensitive	1			
NRTI, TDF, Resistant	0			
PI, Atazanavir (ATV), Sensitive	1			
PI, ATV, Resistant	0			
PI, Darunavir (DRV), Sensitive	1			
PI, DRV, Resistant	0			
PI, Fosamprenavir (FPV), Sensitive	1			
PI, FPV, Resistant	0			
PI, Indinavir (IDV), Sensitive	1			
PI, IDV, Resistant	0			
PI, Lopinavir (LPV), Sensitive	1			
PI, LPV, Resistant	0			
PI, Nelfinavir (NFV), Sensitive	1			
PI, NFV, Resistant	0			
PI, Ritonavir (RTV), Sensitive	1			
PI, RTV, Resistant	0			
PI, Saquinavir (SQV), Sensitive	1			
PI, SQV, Resistant	0			
PI, Tipranavir (TPV), Sensitive	1			
PI, TPV, Resistant	0			

Notes:

[78] - CVW Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Phenotypic Resistance: Up to Week 144

End point title	Number of Participants With Phenotypic Resistance: Up to Week 144

End point description:

Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with phenotypic resistance to INSTI,NNRT,NRTI and PIwere

summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences), which provided the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The phenotypic resistance was calculated using binary scoring system, where 0 was considered as sensitive and 1 as resistance. Phenotypic Resistance data for the following INSTI, NNRTI, NRTI and PI drugs in participants Meeting CVW Criteria has been presented. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable.

End point type	Secondary
End point timeframe:	
Up to Week 144	

End point values	TAF Based Regimen (Early Switch)			
Subject group type	Subject analysis set			
Number of subjects analysed	2[79]			
Units: Participants				
INSTI, DTG, Sensitive	2			
INSTI, DTG, Resistant	0			
INSTI, Bictegravir (BIC), Sensitive	2			
INSTI, BIC, Resistant	0			
INSTI, Elvitegravir (EVG), Sensitive	2			
INSTI, EVG, Resistant	0			
INSTI, Raltegravir (RAL), Sensitive	2			
INSTI, RAL, Resistant	0			
NNRTI, Delavirdine (DLV), Sensitive	2			
NNRTI, DLV, Resistant	0			
NNRTI, Efavirenz (EFV), Sensitive	2			
NNRTI, EFV, Resistant	0			
NNRTI, Etravirine (ETR), Sensitive	2			
NNRTI, ETR, Resistant	0			
NNRTI, Nevirapine (NVP), Sensitive	2			
NNRTI, NVP, Resistant	0			
NNRTI, Rilpivirine (RPV), Sensitive	2			
NNRTI, RPV, Resistant	0			
NRTI, 3TC, Sensitive	2			
NRTI, 3TC, Resistant	0			
NRTI, Abacavir (ABC), Sensitive	2			
NRTI, ABC, Resistant	0			
NRTI, Zidovudine (AZT), Sensitive	2			
NRTI, AZT, Resistant	0			
NRTI, Stavudine (D4T), Sensitive	2			
NRTI, D4T, Resistant	0			
NRTI, Didanosine (DDI), Sensitive	2			
NRTI, DDI, Resistant	0			
NRTI, Emtricitabine (FTC), Sensitive	2			
NRTI, FTC, Resistant	0			
NRTI, Tenofovir (TDF), Sensitive	2			
NRTI, TDF, Resistant	0			
PI, Atazanavir (ATV), Sensitive	2			

PI, ATV, Resistant	0			
PI, Darunavir (DRV), Sensitive	2			
PI, DRV, Resistant	0			
PI, Fosamprenavir (FPV), Sensitive	2			
PI, FPV, Resistant	0			
PI, Indinavir (IDV), Sensitive	2			
PI, IDV, Resistant	0			
PI, Lopinavir (LPV), Sensitive	2			
PI, LPV, Resistant	0			
PI, Nelfinavir (NFV), Sensitive	2			
PI, NFV, Resistant	0			
PI, Ritonavir (RTV), Sensitive	2			
PI, RTV, Resistant	0			
PI, Saquinavir (SQV), Sensitive	2			
PI, SQV, Resistant	0			
PI, Tipranavir (TPV), Sensitive	2			
PI, TPV, Resistant	0			

Notes:

[79] - CVW Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum procollagen 1 N-Terminal propeptide (P1NP) and serum type 1 collagen C-telopeptides (CTX-1) at Weeks 24 and 48

End point title	Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum procollagen 1 N-Terminal propeptide (P1NP) and serum type 1 collagen C-telopeptides (CTX-1) at Weeks 24 and 48

End point description:

Baseline was (Day 1).Change from Baseline is post-dose visit value - Baseline value.Adjusted mean was estimated mean change from Baseline at each visit calculated from a repeated measures model adjusting for treatment, visit,Baseline third agent class, CD4+ cell count(continuous),age(continuous),sex,race,body mass index(BMI,continuous),smoking status, vitaminD use, Baseline biomarker(continuous),treatment by visit interaction,& Baseline value by visit interaction,with visit as repeated factor.1 participant randomized to TBR but received TDF & because safety profiles of TDF & TAF differ, participant was removed from overall safety population & presented in separate arm"Randomized to TBR but received TDF-based regimen''.Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure & 1 participant is presented separately in next Outcome Measure.Only those participants with data available at specified data points

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC	TAF-based regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	369[80]	371[81]		
Units: Micrograms per liter				
arithmetic mean (standard error)				
Bone-ALP, Week 24, n=350, 354	-0.77 (± 0.112)	-1.05 (± 0.089)		
Bone-ALP, Week 48, n=343, 342	-0.03 (± 0.145)	-0.34 (± 0.117)		
Osteocalcin, Week 24, n=350 ,353	-1.08 (± 0.248)	0.26 (± 0.229)		
Osteocalcin, Week 48, n=343, 342	-1.15 (± 0.260)	0.69 (± 0.279)		
P1NP, Week24, n=349 ,356	7.0 (± 0.87)	5.0 (± 0.72)		
P1NP, Week48, n=342, 343	9.3 (± 1.06)	6.4 (± 1.00)		
CTX-1, Week 24,n=350,356	0.0350 (± 0.01057)	-0.0031 (± 0.00833)		
CTX-1, Week 48, n=343, 343	0.0602 (± 0.01024)	0.0310 (± 0.00889)		

Notes:

[80] - Safety Population.

[81] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Bone-ALP at Week 24 has been presented	
Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.047
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.57

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Bone-ALP at Week 48 has been presented	
Comparison groups	DTG+3TC FDC v TAF-based regimen

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.094
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.68

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Osteocalcin at Week 24 has been presented	
Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.01
upper limit	-0.68

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for CTX-1 at Week 48 has been presented	
Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.032
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0292

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.0025
upper limit	0.0559

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for P1NP at Week 24 has been presented	
Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.066
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	4.3

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for P1NP at Week 48 has been presented.	
Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.046
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	5.8

Statistical analysis title	Statistical Analysis 7

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for CTX-1 at Week 24 has been presented.

Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0381
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.0117
upper limit	0.0646

Statistical analysis title	Statistical Analysis 4

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Osteocalcin at Week 48 has been presented

Comparison groups	DTG+3TC FDC v TAF-based regimen
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.59
upper limit	-1.09

Secondary: Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum P1NP and serum CTX-1 in participants randomized to TBR arm receiving TDF-based regimen at Weeks 24 and 48

End point title	Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum P1NP and serum CTX-1 in participants randomized to TBR arm receiving TDF-based regimen at Weeks 24 and 48

End point description:

Serum samples were collected for analysis of bone biomarkers. Baseline was latest pre-dose assessment with a non-missing value (Day 1) . Change from Baseline is post-dose visit value minus Baseline value. Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum P1NP and serum CTX-1 in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." Only those participants with data available at

the specified data points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[82]			
Units: Micrograms per liter				
number (not applicable)				
Bone-ALP, Week 24, n=1	0.3			
Bone-ALP, Week 48, n=0	99999			
Osteocalcin, Week 24, n=1	13.4			
Osteocalcin, Week 48, n=0	99999			
P1NP, Week24, n=1	11			
P1NP, Week48, n=0	99999			
CTX-1, Week 24,n=1	0.045			
CTX-1, Week 48, n=0	99999			

Notes:

[82] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in bone biomarkers-serum Bone-ALP, osteocalcin, serum P1NP and serum type 1 CTX-1 at Weeks 96 and 144

End point title	Change from Baseline in bone biomarkers-serum Bone-ALP, osteocalcin, serum P1NP and serum type 1 CTX-1 at Weeks 96 and 144

End point description:

Serum samples were collected for analysis of bone biomarkers. Baseline is latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen"). Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[83]	371[84]		
Units: Micrograms per liter				
arithmetic mean (standard error)				
Bone-ALP, Week 96, n=316, 289	-0.62 (± 0.145)	-0.79 (± 0.137)		
Bone-ALP, Week 144, n=314, 301	-0.27 (± 0.163)	-0.40 (± 0.177)		
Osteocalcin, Week 96, n=315 , 288	-1.97 (± 0.288)	-0.10 (± 0.306)		
Osteocalcin, Week 144, n=315, 301	-0.74 (± 0.266)	1.21 (± 0.320)		
P1NP, Week 96, n=316 ,290	6.7 (± 0.87)	4.7 (± 0.80)		
P1NP, Week 144, n=315, 302	3.9 (± 0.94)	3.5 (± 1.04)		
CTX-1, Week 96 ,n=315, 289	0.0201 (± 0.01123)	0.0050 (± 0.00929)		
CTX-1, Week 48, n=315, 300	0.0022 (± 0.00947)	-0.0104 (± 0.00907)		

Notes:

[83] - Safety Population.

[84] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Bone-ALP at Week 144 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.573
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.34
upper limit	0.61

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Bone-ALP at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.386
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.57

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Osteocalcin at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	-1.04

Statistical analysis title	Statistical Analysis 8
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for CTX-1 at Week 144 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.34
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0126

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0133
upper limit	0.0384

Statistical analysis title	Statistical Analysis 6
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for P1NP at Week 144 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.765
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	3.2

Statistical analysis title	Statistical Analysis 5
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for P1NP at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.082
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	4.4

Statistical analysis title	Statistical Analysis 4

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for Osteocalcin at Week 144 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.77
upper limit	-1.14

Statistical analysis title	Statistical Analysis 7

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for CTX-1 at Week 96 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.301
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0151
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0136
upper limit	0.0438

Secondary: Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 24 and 48

End point title	Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 24 and 48

End point description:

Serum samples were collected to assess renal biomarker. Baseline was latest pre-dose assessment value with non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for following:treatment, visit, Baseline third agent class, CD4+ cell count(continuous), age(continuous), sex, race, BMI(continuous), presence of diabetes mellitus, presence of hypertension, Baseline biomarker(continuous), treatment by visit interaction, & Baseline value by visit interaction, with visit as repeated factor. One participant randomized to TBR but received TDF-based regimen and

because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen"

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[85]	371[86]		
Units: Nanomoles per liter				
arithmetic mean (standard error)				
Week 24, n=351, 355	0.0 (± 1.10)	2.1 (± 1.15)		
Week 48, n=344, 343	-5.8 (± 1.21)	-3.5 (± 1.13)		

Notes:

[85] - Safety Population.

[86] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum 25 hydroxyvitamin D at Week 48 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.168
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.5
upper limit	1

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum 25 hydroxyvitamin D at Week 24 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.173
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	1

Secondary: Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Serum samples were collected for the analysis of 25-hydroxyvitamin D. Baseline value was the value from latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for serum 25-hydroxyvitamin D in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen." 99999 indicates data is not available. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[87]			
Units: Nanomoles per liter				
Week 24, n=1	2			
Week 48, n=0	99999			

Notes:

[87] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 96 and 144

End point title	Change from Baseline in bone biomarker: serum 25-hydroxyvitamin D at Weeks 96 and 144

End point description:

Baseline value was (Day 1).Change from Baseline is post-dose visit value minus Baseline value.Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit, Baseline third agent class,CD4+ cell count(continuous),age(continuous),sex, race, BMI(continuous),smoking status, vitaminD use,Baseline biomarker(continuous),treatment by visit interaction,& Baseline value by visit interaction, with visit as repeated factor.1 participant randomized to TBR but received TDF & because safety profiles of TDF & TAF differ, participant was removed from overall safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen.Total of 741 participants were analyzed but 740 participants presented in this Outcome Measure & 1 participant is presented separately in next Outcome Measure. Only those participants with data available at specified data points analyzed(n=X in category

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[88]	371[89]		
Units: Nanomoles per liter				
arithmetic mean (standard error)				
Week 96, n=315, 291	-11.5 (± 1.17)	-2.2 (± 2.06)		
Week 144, n=315, 303	-7.5 (± 1.28)	-1.9 (± 1.50)		

Notes:

[88] - Safety Population.

[89] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum 25 hydroxyvitamin D at Week 144 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.005
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-5.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.4
upper limit	-1.7

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum 25 hydroxyvitamin D at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-9.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14
upper limit	-4.7

Secondary: Change from Baseline in renal biomarker- serum cystatin C at Weeks 24 and 48

End point title	Change from Baseline in renal biomarker- serum cystatin C at Weeks 24 and 48

End point description:

Serum samples were collected to assess renal biomarker.Baseline was latest pre-dose assessment value with non-missing value (Day 1).Change from Baseline is post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for following:treatment, visit, Baseline third agent class, CD4+ cell count(continuous), age(continuous), sex, race, BMI(continuous), presence of diabetes mellitus, presence of hypertension, Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen"

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[90]	371[91]		
Units: Milligrams per liter				
arithmetic mean (standard error)				
Week 24, n=351, 357	-0.03 (± 0.005)	-0.02 (± 0.004)		

Week 48, n=344, 343	0.00 (± 0.006)	0.01 (± 0.005)		

Notes:

[90] - Safety Population.

[91] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum cystatin C at Week 48 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.061
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum cystatin C at Week 24 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.027
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0

Secondary: Change from Baseline in renal biomarker- serum cystatin C at Weeks 24

and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in renal biomarker- serum cystatin C at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Serum samples were collected at Baseline, Week 24 and Week 48 to assess renal inflammation biomarker - cystatin C. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for serum cystatin -C biomarker in TDF based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen."99999 indicates data is not available. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[92]			
Units: Milligrams per liter				
Week 24, n=1	0			
Week 48, n=0	99999			

Notes:

[92] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarker- serum cystatin C at Weeks 96 and 144

End point title	Change from Baseline in renal biomarker- serum cystatin C at Weeks 96 and 144

End point description:

Change from Baseline is post-dose visit value - Baseline value.Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for following:treatment, visit, Baseline third agent class,CD4+ cell count(continuous), age(continuous),sex,race,BMI(continuous),presence of diabetes mellitus, hypertension,Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit repeated factor.1 participant randomized to TBR but received TDF and because safety profiles of TDF and TAF differ, participant was removed from overall safety population and presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Participants with data available at specified data points were analyzed(n=X in

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[93]	371[94]		
Units: Milligrams per liter				
arithmetic mean (standard error)				
Week 96, n=316, 290	0.07 (± 0.008)	0.10 (± 0.009)		
Week 144, n=315, 302	0.13 (± 0.006)	0.14 (± 0.006)		

Notes:

[93] - Safety Population.

[94] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum cystatin C at Week 144 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.094
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum cystatin C at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.004
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	-0.01

Secondary: Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 24 and 48

End point title	Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 24 and 48

End point description:

Change from Baseline is post-dose visit value - Baseline value. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit,Baseline third agent class,CD4+ cell count(continuous), age(continuous), sex, race,BMI(continuous), presence of diabetes mellitus, hypertension, Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor. 1 participant randomized to TBR but received TDF and because safety profiles of TDF and TAF differ, participant was removed from overall safety population and presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure.Participants with data available at specified data points were analyzed (n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[95]	371[96]		
Units: Milliliters/minute/1.73*meter square				
arithmetic mean (standard error)				
GFR from cystatin C CKD-EPI, Week 24, n=351, 357	3.2 (± 0.52)	1.5 (± 0.46)		
GFR from cystatin C CKD-EPI, Week 48, n=344, 343	0.1 (± 0.61)	-1.6 (± 0.59)		
GFR from creatinine CKD-EPI, Week 24, n=351, 359	-8.8 (± 0.48)	-3.8 (± 0.47)		
GFR from creatinine CKD-EPI, Week 48, n=344, 345	-7.7 (± 0.48)	-2.9 (± 0.48)		

Notes:

[95] - Safety Population.

[96] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from cystatin C adjusted using CKD-EPI at Week 24 has been presented

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.012
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	3.1

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from creatinine adjusted using CKD-EPI at Week 48 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-4.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	-3.4

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from creatinine adjusted using CKD-EPI at Week 24 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.3
upper limit	-3.7

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from cystatin C adjusted using CKD-EPI at Week 48 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.059
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	3.3

Secondary: Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Serum samples were collected to assess renal inflammation biomarkers - serum GFR from cystatin C adjusted using CKD-EPI & serum GFR from creatinine adjusted using CKD-EPI. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline in serum GFR from cystatin C adjusted using CKD-EPI & serum GFR from creatinine adjusted using CKD-EPI in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen & because the safety profiles of TDF & TAF differ, this participant was removed from the overall safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen.” Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[97]			
Units: Milliliters/minute/1.73*meter square				
GFR from cystatin C CKD-EPI, Week 24, n=1	0			
GFR from cystatin C CKD-EPI, Week 48, n=0	99999			
GFR from creatinine CKD-EPI, Week 24, n=1	4			
GFR from creatinine CKD-EPI, Week 48, n=0	99999			

Notes:

[97] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 96 and 144

End point title	Change from Baseline in renal biomarker- serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI at Weeks 96 and 144

End point description:

Change from Baseline is post-dose visit value - Baseline value.Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for following:treatment, visit, Baseline third agent class,CD4+ cell count(continuous), age(continuous),sex,race,BMI(continuous),presence of diabetes mellitus, hypertension,Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit repeated factor.1 participant randomized to TBR but received TDF and because safety profiles of TDF and TAF differ, participant was removed from overall safety population and presented in separate arm "Randomized to TBR but received TDF-based regimen." Total of 741 participants were analyzed but 740 participants are presented in this Outcome Measure and 1 participant is presented separately in next Outcome Measure. Participants with data available at specified data points were analyzed(n=X in

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[98]	371[99]		
Units: Milliliters/minute/1.73*meter square				
arithmetic mean (standard error)				
Cystatin C CKD-EPI,Week 96,n=316, 290	-7.6 (± 0.89)	-11.7 (± 0.99)		
Cystatin C CKD-EPI,Week 144,n=315, 302	-13.9 (± 0.71)	-15.8 (± 0.70)		
Creatinine adjusted for BSA,Week 96,n=315, 294	-7.2 (± 0.55)	-1.9 (± 0.52)		
Creatinine adjusted for BSA,Week 144,n=311, 300	-11.5 (± 0.62)	-7.0 (± 0.60)		

Notes:

[98] - Safety Population.

[99] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from cystatin C adjusted using CKD-EPI at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.5
upper limit	6.7

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from cystatin C adjusted using CKD-EPI at Week 148 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.064
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	3.8

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from creatinine adjusted using CKD-EPI at Week 96 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.7
upper limit	-3.8

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Mean difference (DTG+3TC - TAF based regimen) and its 95% CI for serum GFR from creatinine adjusted using CKD-EPI at Week 144 has been presented	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-4.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	-2.8

Secondary: Change from Baseline in renal biomarker- serum creatinine at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point title	Change from Baseline in renal biomarker- serum creatinine at Weeks 24 and 48 in participants randomized to TBR arm receiving TDF-based regimen

End point description:

Serum samples were collected at Baseline, Week 24 and Week 48 to assess renal inflammation biomarker - serum creatinine. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline in serum creatinine in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm "Randomized to TBR but received TDF-based regimen.”99999 indicates data is not available. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data not collected post week 48 as the participant withdrew from the study.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	Randomized to TBR But Received TDF-based Regimen(Early			
Subject group type	Subject analysis set			
Number of subjects analysed	1[100]			
Units: Micromoles per liter				
number (not applicable)				
Week 24, n=1	-8			
Week 48, n=0	99999			

Notes:

[100] - Safety Population.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in renal biomarker- serum creatinine at Weeks 24 and 48

End point title	Change from Baseline in renal biomarker- serum creatinine at Weeks 24 and 48

End point description:

Baseline(Day 1)was value from latest pre-dose assessment with non-missing value.Change from Baseline is post-dose visit value - Baselinevalue.Adjusted mean was estimated mean change from

Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit,Baseline third agent class,CD4+ cell count(continuous),age(continuous),sex,race, BMI(continuous),diabetes mellitus,hypertension,Baseline biomarker(continuous),treatment by visit interaction,&Baseline value by visit interaction, with visit as repeated factor. 1participant randomized toTBR butreceived TDF as safety profiles ofTDF & TAFdiffer,participant was removed from safety population & presented in separate arm Randomized to TBR but received TDF-based regimen.Only those participants with data available at specified data points were analyzed(n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[101]	371[102]		
Units: Micromoles per liter				
arithmetic mean (standard error)				
Week 24, n=351, 359	7.47 (± 0.466)	3.11 (± 0.495)		
Week 48, n=344, 345	6.67 (± 0.493)	2.18 (± 0.450)		

Notes:

[101] - Safety Population.

[102] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Mean difference (DTG+3TC - TBR) and its 95% CI for serum creatinine at Week 48 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	4.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.18
upper limit	5.81

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mean difference (DTG+3TC - TBR) and its 95% CI for serum creatinine at Week 24 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	4.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.03
upper limit	5.7

Secondary: Change from Baseline in renal biomarker- serum creatinine at Weeks 96 and 144

End point title	Change from Baseline in renal biomarker- serum creatinine at Weeks 96 and 144

End point description:

Baseline(Day 1)was value from latest pre-dose assessment with non-missing value.Change from Baseline is post-dose visit value - Baselinevalue.Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit,Baseline third agent class,CD4+ cell count(continuous),age(continuous),sex,race, BMI(continuous),diabetes mellitus,hypertension,Baseline biomarker(continuous),treatment by visit interaction,&Baseline value by visit interaction, with visit as repeated factor. 1participant randomized toTBR butreceived TDF as safety profiles ofTDF & TAFdiffer,participant was removed from safety population & presented in separate arm Randomized to TBR but received TDF-based regimen.Only those participants with data available at specified data points were analyzed(n=X in category titles).

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[103]	371[104]		
Units: Micromoles per liter				
arithmetic mean (standard error)				
Week 96, n=316, 294	5.53 (± 0.553)	0.58 (± 0.515)		
Week 144, n=311, 302	9.25 (± 0.637)	5.17 (± 0.633)		

Notes:

[103] - Safety Population.

[104] - Safety Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Mean difference (DTG+3TC - TBR) and its 95% CI for serum creatinine at Week 144 has been presented.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	4.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.32
upper limit	5.85

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Mean difference (DTG+3TC - TBR) and its 95% CI for serum creatinine at Week 96 has been presented.	
Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	740
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	4.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.47
upper limit	6.43

Secondary: Change from Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) utility score at Week 24 and 48

End point title	Change from Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) utility score at Week 24 and 48

End point description:

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. Fiveitem measure has 1 question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. Health state is defined by combining levels of answers from each of 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. One participant randomized to TBR but received TDF and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable. Only those participants with data available at specified time points has been analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	364[105]	370[106]		
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 24	0.0029 (± 0.00383)	0.0046 (± 0.00352)		
Week 48	0.0037 (± 0.00407)	0.0023 (± 0.00373)		

Notes:

[105] - ITT-E Population.

[106] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 48. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Utility (continuous), Treatment by Visit interaction, and Baseline EQ-5D Utility by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	734
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.792
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0015
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0094
upper limit	0.0123

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 24. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Utility (continuous), Treatment by Visit interaction, and Baseline EQ-5D Utility by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	734
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.741
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.0017
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0119
upper limit	0.0085

Secondary: Change from Baseline in EQ-5D-5L Thermometer scores at Week 24 and 48

End point title	Change from Baseline in EQ-5D-5L Thermometer scores at Week 24 and 48

End point description:

EEQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the "TBR (TAF-based regimen) arm" as efficacy of TAF and TDF are comparable. Participants with data available at specified time points has been analyzed.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 24 and 48

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	364[107]	369[108]		
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 24	1.2 (± 0.49)	1.3 (± 0.44)		
Week 48	1.1 (± 0.52)	1.7 (± 0.43)		

Notes:

[107] - ITT-E Population.

[108] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 48. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Thermometer (continuous), Treatment by Visit interaction, and Baseline EQ-5D Thermometer by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	733
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.414
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	0.8

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 24. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Thermometer (continuous), Treatment by Visit interaction, and Baseline EQ-5D Thermometer by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	733
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.879
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	1.2

Secondary: Change from Baseline in EQ-5D-5L utility score at Weeks 96 and 144

End point title	Change from Baseline in EQ-5D-5L utility score at Weeks 96 and 144

End point description:

EQ-5D-5L questionnaire provides profile of participant function and global health state rating. Five-item measure has 1question assessing each of 5dimensions:mobility,self-care,usual activities,pain/discomfort,anxiety/depression and 5 levels for each dimension including 1=no problems,2=slight problems,3=moderate problems,4=severe problems,5=extreme problems. Health state is defined by combining levels of answers from each of 5 questions. Each health state is referred to in terms of a 5 digit code.Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state.EQ-5D-5L utility score ranges from -0.281 to 1. Higher

scores indicate better health.Baseline is latest pre-dose assessment value with a non-missing value (Day 1).Change from Baseline is post-dose visit value minus Baseline value.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[109]	372[110]		
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 96, n=364, 370	-0.0036 (± 0.00442)	-0.0038 (± 0.00446)		
Week 144, n=364, 369	-0.0151 (± 0.00502)	-0.0042 (± 0.00492)		

Notes:

[109] - ITT-E Population.

[110] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 144. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Utility (continuous), Treatment by Visit interaction, and Baseline EQ-5D Utility by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	741
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.12
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-0.0109
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0247
upper limit	0.0029

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 96. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Utility (continuous), Treatment by Visit interaction, and Baseline EQ-5D Utility by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)

Number of subjects included in analysis	741
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.965
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	0.0003
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0121
upper limit	0.0126

Secondary: Change from Baseline in EQ-5D-5L Thermometer scores at Weeks 96 and 144

End point title	Change from Baseline in EQ-5D-5L Thermometer scores at Weeks 96 and 144

End point description:

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. ITT-E Population.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and at Weeks 96 and 144

End point values	DTG+3TC FDC (Early switch)	TAF Based Regimen (Early switch)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	369[111]	372[112]		
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 96, n=364, 369	0.7 (± 0.52)	1.9 (± 0.48)		
Week 144, n=364, 368	0.2 (± 0.58)	1.4 (± 0.50)		

Notes:

[111] - ITT-E Population.

[112] - ITT-E Population.

Statistical analyses

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

Week 144. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Thermometer (continuous), Treatment by Visit interaction, and Baseline EQ-5D Thermometer by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	741
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.093
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	0.2

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Week 96. MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Baseline EQ-5D Thermometer (continuous), Treatment by Visit interaction, and Baseline EQ-5D Thermometer by Visit interaction, with Visit as the repeated factor.

Comparison groups	DTG+3TC FDC (Early switch) v TAF Based Regimen (Early switch)
Number of subjects included in analysis	741
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.102
Method	Mixed Model Repeated Measures
Parameter estimate	Mean difference (net)
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.2

Adverse events

Adverse events information

Timeframe for reporting adverse events:

TAF Based Regimen EarlySwitch uptoWeek 148; Randomized to TBR but received TDFbased regimen uptoweek 48;DTG+3TC FDC Early+Late Switch-Overall uptoWeek 196, TAF Based Regimen(Early Switch) then DTG+3TC FDC(Late Switch) from Week 148 to Week 196

Adverse event reporting additional description:

Safety Population. 1 participant randomized to TBR received TDF based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the safety population & is presented in separate arm "Randomized to TBR but received TDF-based regimen (Early switch)"

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups

Reporting group title	TAF Based Regimen (Early Switch)

Reporting group description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase.

Reporting group title	DTG + 3TC FDC (Early Switch + Late Switch)-Overall

Reporting group description:

Participants who were on a stable TBR and who had an HIV-1 ribonucleic acid (RNA) <50 copies per millilter (c/mL) at the time of screening, received fixed dose combination of DTG 50 mg + 3TC 300 mg once daily up to 196 weeks during early and late switch phase.

Reporting group title	TAF Based Regimen(Early Switch) then DTG+3TC FDC(Late Switch)

Reporting group description:

Participants who were on a stable TBR and who had an HIV-1 RNA<50 c/mL at the time of screening, were continued to receive TBR up to 148 weeks during early switch phase. At Week 148 (or upon retest) were switched to DTG/3TC FDC once daily up to Week 196 during late switch phase.

Reporting group title	Randomized to TBR but received TDF-based regimen(Early Switch)

Reporting group description:

Participant randomized to TBR arm who had HIV-1 RNA <50 c/mL at the time of screening, received TDF-based regimen instead of TAF-based regimen in error. Participant continued to receive TDF-regimen up to the Week 48 visit (participant withdrew from the study at Week 36).

Serious adverse events	TAF Based Regimen (Early Switch)	DTG + 3TC FDC (Early Switch + Late Switch)-Overall	TAF Based Regimen(Early Switch) then DTG+3TC FDC(Late
Total subjects affected by serious adverse events			
subjects affected / exposed	44 / 371 (11.86%)	65 / 369 (17.62%)	15 / 298 (5.03%)
number of deaths (all causes)	0	4	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			

subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	0 / 371 (0.00%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to liver			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile squamous cell carcinoma			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	0 / 371 (0.00%)	3 / 369 (0.81%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burkitt's lymphoma stage I			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			

subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine adenocarcinoma			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland neoplasm			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Premature labour			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Type I hypersensitivity			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian haematoma			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			

subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	2 / 371 (0.54%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Priapism			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	3 / 371 (0.81%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord cyst			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Suicidal ideation			
subjects affected / exposed	2 / 371 (0.54%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	2 / 371 (0.54%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 371 (0.27%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			
subjects affected / exposed	3 / 371 (0.81%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar II disorder			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance abuse			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Injury, poisoning and procedural complications			

Gun shot wound			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound evisceration			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			

subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Hydrocele			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Cerebral haematoma			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 371 (0.00%)	4 / 369 (1.08%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukoencephalopathy			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegic migraine			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bell's palsy			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Inguinal hernia			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	2 / 371 (0.54%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Cholecystitis			
subjects affected / exposed	2 / 371 (0.54%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	2 / 371 (0.54%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary dyskinesia			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 371 (0.00%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic hepatitis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Calculus urinary			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteitis			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 371 (0.00%)	2 / 369 (0.54%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nose deformity			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliac joint dysfunction			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical spinal stenosis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 371 (0.27%)	3 / 369 (0.81%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 371 (0.27%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amniotic cavity infection			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis pneumococcal			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shigella infection			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pertussis			

subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal perforated			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis gonococcal			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	2 / 371 (0.54%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 371 (0.00%)	2 / 369 (0.54%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	2 / 371 (0.54%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 371 (0.54%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal abscess			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute hepatitis C			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal abscess			

subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal abscess			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 371 (0.27%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syphilis			
subjects affected / exposed	0 / 371 (0.00%)	0 / 369 (0.00%)	1 / 298 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			

subjects affected / exposed	0 / 371 (0.00%)	1 / 369 (0.27%)	0 / 298 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Randomized to TBR but received TDF-based regimen(Early Switch)		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to liver			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Penile squamous cell carcinoma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease			

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Burkitt's lymphoma stage I				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal tract adenoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of lung				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestine adenocarcinoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adenocarcinoma of colon				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Salivary gland neoplasm				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cell carcinoma				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostate cancer				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic carcinoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
Deep vein thrombosis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypovolaemic shock				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive crisis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pregnancy, puerperium and perinatal conditions				
Premature labour				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
Non-cardiac chest pain				

subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Type I hypersensitivity			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Ovarian haematoma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cyst			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Priapism			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vocal cord cyst				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary hypertension				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atelectasis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
Suicidal ideation				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anxiety				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Depression				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Suicide attempt				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bipolar disorder				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bipolar II disorder				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Major depression				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Substance abuse				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Gun shot wound				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femoral neck fracture				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Overdose				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Craniocerebral injury				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Foot fracture				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wrist fracture				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound evisceration				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tendon rupture				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural haematoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Humerus fracture				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Congenital, familial and genetic disorders				
Hydrocele				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				
Acute myocardial infarction				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Atrial fibrillation				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular tachycardia				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial infarction				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
Cerebral haematoma				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalopathy				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Syncope				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sciatica				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Leukoencephalopathy				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemiplegic migraine				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Headache				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bell's palsy				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Loss of consciousness				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ear and labyrinth disorders				
Vertigo				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Inguinal hernia				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal hernia				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
Cholecystitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholelithiasis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Biliary dyskinesia				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis acute				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertransaminasaemia				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ischaemic hepatitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin and subcutaneous tissue disorders				
Angioedema				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal and urinary disorders				
Nephrolithiasis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Calculus urinary				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute kidney injury				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal and connective tissue disorders				
Osteitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral disc protrusion				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Nose deformity				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteoarthritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sacroiliac joint dysfunction				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cervical spinal stenosis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Pneumonia				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anal abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Amniotic cavity infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Labyrinthitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningitis pneumococcal				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia sepsis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Shigella infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pertussis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis intestinal perforated				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19 pneumonia				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis gonococcal				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Scrotal abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal abscess				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute hepatitis C				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Groin abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perirectal abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perineal abscess				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subcutaneous abscess				

subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syphilis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertriglyceridaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	TAF Based Regimen (Early Switch)	DTG + 3TC FDC (Early Switch + Late Switch)-Overall	TAF Based Regimen(Early Switch) then DTG+3TC FDC(Late
Total subjects affected by non-serious adverse events			
subjects affected / exposed	304 / 371 (81.94%)	327 / 369 (88.62%)	187 / 298 (62.75%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	10 / 371 (2.70%)	9 / 369 (2.44%)	3 / 298 (1.01%)
occurrences (all)	11	10	3
Vascular disorders			
Hypertension			

subjects affected / exposed	15 / 371 (4.04%)	26 / 369 (7.05%)	7 / 298 (2.35%)
occurrences (all)	15	28	7
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	11 / 371 (2.96%)	32 / 369 (8.67%)	11 / 298 (3.69%)
occurrences (all)	12	33	11
Chest pain			
subjects affected / exposed	9 / 371 (2.43%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	10	10	1
Influenza like illness			
subjects affected / exposed	13 / 371 (3.50%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	16	0	0
Pyrexia			
subjects affected / exposed	14 / 371 (3.77%)	19 / 369 (5.15%)	7 / 298 (2.35%)
occurrences (all)	15	20	8
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	4 / 371 (1.08%)	15 / 369 (4.07%)	3 / 298 (1.01%)
occurrences (all)	5	18	3
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	19 / 371 (5.12%)	15 / 369 (4.07%)	3 / 298 (1.01%)
occurrences (all)	20	15	3
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	20 / 371 (5.39%)	27 / 369 (7.32%)	5 / 298 (1.68%)
occurrences (all)	21	30	5
Oropharyngeal pain			
subjects affected / exposed	17 / 371 (4.58%)	15 / 369 (4.07%)	2 / 298 (0.67%)
occurrences (all)	17	19	2
Psychiatric disorders			
Anxiety			
subjects affected / exposed	29 / 371 (7.82%)	43 / 369 (11.65%)	7 / 298 (2.35%)
occurrences (all)	30	44	8
Insomnia			

subjects affected / exposed	18 / 371 (4.85%)	29 / 369 (7.86%)	7 / 298 (2.35%)
occurrences (all)	18	34	8
Depression			
subjects affected / exposed	21 / 371 (5.66%)	31 / 369 (8.40%)	6 / 298 (2.01%)
occurrences (all)	24	32	6
Investigations			
Weight increased			
subjects affected / exposed	19 / 371 (5.12%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	19	9	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	9	0	0
Ligament sprain			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	5 / 298 (1.68%)
occurrences (all)	0	8	5
Arthropod bite			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	9	0	0
Muscle strain			
subjects affected / exposed	4 / 371 (1.08%)	8 / 369 (2.17%)	1 / 298 (0.34%)
occurrences (all)	4	8	1
Limb injury			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	8	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	23 / 371 (6.20%)	41 / 369 (11.11%)	17 / 298 (5.70%)
occurrences (all)	33	54	20
Dizziness			
subjects affected / exposed	11 / 371 (2.96%)	15 / 369 (4.07%)	5 / 298 (1.68%)
occurrences (all)	11	15	5
Migraine			
subjects affected / exposed	5 / 371 (1.35%)	9 / 369 (2.44%)	2 / 298 (0.67%)
occurrences (all)	5	10	2
Ear and labyrinth disorders			

Ear pain			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	8	0	0
Vertigo			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	3 / 298 (1.01%)
occurrences (all)	0	8	3
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	43 / 371 (11.59%)	54 / 369 (14.63%)	12 / 298 (4.03%)
occurrences (all)	55	70	12
Vomiting			
subjects affected / exposed	6 / 371 (1.62%)	12 / 369 (3.25%)	2 / 298 (0.67%)
occurrences (all)	6	12	2
Constipation			
subjects affected / exposed	7 / 371 (1.89%)	15 / 369 (4.07%)	1 / 298 (0.34%)
occurrences (all)	7	19	1
Toothache			
subjects affected / exposed	16 / 371 (4.31%)	13 / 369 (3.52%)	4 / 298 (1.34%)
occurrences (all)	19	15	5
Abdominal pain			
subjects affected / exposed	14 / 371 (3.77%)	19 / 369 (5.15%)	2 / 298 (0.67%)
occurrences (all)	15	21	2
Nausea			
subjects affected / exposed	18 / 371 (4.85%)	23 / 369 (6.23%)	4 / 298 (1.34%)
occurrences (all)	20	25	4
Gastrooesophageal reflux disease			
subjects affected / exposed	9 / 371 (2.43%)	20 / 369 (5.42%)	6 / 298 (2.01%)
occurrences (all)	12	20	6
Haemorrhoids			
subjects affected / exposed	12 / 371 (3.23%)	14 / 369 (3.79%)	5 / 298 (1.68%)
occurrences (all)	12	14	5
Abdominal pain upper			
subjects affected / exposed	9 / 371 (2.43%)	11 / 369 (2.98%)	3 / 298 (1.01%)
occurrences (all)	9	13	3
Dyspepsia			

subjects affected / exposed	5 / 371 (1.35%)	10 / 369 (2.71%)	1 / 298 (0.34%)
occurrences (all)	5	10	1
Abdominal distension			
subjects affected / exposed	6 / 371 (1.62%)	10 / 369 (2.71%)	2 / 298 (0.67%)
occurrences (all)	6	11	2
Proctalgia			
subjects affected / exposed	9 / 371 (2.43%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	9	0	0
Dental caries			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	9	0	0
Gastritis			
subjects affected / exposed	0 / 371 (0.00%)	9 / 369 (2.44%)	3 / 298 (1.01%)
occurrences (all)	0	9	3
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	2 / 298 (0.67%)
occurrences (all)	0	12	2
Dry skin			
subjects affected / exposed	8 / 371 (2.16%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	9	0	0
Dermatitis			
subjects affected / exposed	10 / 371 (2.70%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	10	0	0
Rash			
subjects affected / exposed	11 / 371 (2.96%)	15 / 369 (4.07%)	3 / 298 (1.01%)
occurrences (all)	11	17	3
Pruritus			
subjects affected / exposed	12 / 371 (3.23%)	11 / 369 (2.98%)	1 / 298 (0.34%)
occurrences (all)	13	11	1
Dermatitis contact			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	2 / 298 (0.67%)
occurrences (all)	0	8	2
Renal and urinary disorders			
Dysuria			

subjects affected / exposed	0 / 371 (0.00%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	0	9	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	49 / 371 (13.21%)	47 / 369 (12.74%)	11 / 298 (3.69%)
occurrences (all)	63	53	12
Arthralgia			
subjects affected / exposed	39 / 371 (10.51%)	46 / 369 (12.47%)	15 / 298 (5.03%)
occurrences (all)	43	56	17
Pain in extremity			
subjects affected / exposed	14 / 371 (3.77%)	23 / 369 (6.23%)	6 / 298 (2.01%)
occurrences (all)	17	25	7
Myalgia			
subjects affected / exposed	0 / 371 (0.00%)	11 / 369 (2.98%)	4 / 298 (1.34%)
occurrences (all)	0	11	4
Neck pain			
subjects affected / exposed	6 / 371 (1.62%)	9 / 369 (2.44%)	5 / 298 (1.68%)
occurrences (all)	6	11	5
Muscle spasms			
subjects affected / exposed	9 / 371 (2.43%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	10	0	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	42 / 371 (11.32%)	52 / 369 (14.09%)	7 / 298 (2.35%)
occurrences (all)	56	72	7
Nasopharyngitis			
subjects affected / exposed	64 / 371 (17.25%)	71 / 369 (19.24%)	16 / 298 (5.37%)
occurrences (all)	93	109	18
Syphilis			
subjects affected / exposed	33 / 371 (8.89%)	49 / 369 (13.28%)	13 / 298 (4.36%)
occurrences (all)	43	61	13
Pharyngitis			
subjects affected / exposed	22 / 371 (5.93%)	21 / 369 (5.69%)	5 / 298 (1.68%)
occurrences (all)	25	22	5
Bronchitis			

subjects affected / exposed	23 / 371 (6.20%)	17 / 369 (4.61%)	5 / 298 (1.68%)
occurrences (all)	24	19	5
Gastroenteritis			
subjects affected / exposed	23 / 371 (6.20%)	29 / 369 (7.86%)	5 / 298 (1.68%)
occurrences (all)	26	37	5
Oral herpes			
subjects affected / exposed	12 / 371 (3.23%)	10 / 369 (2.71%)	0 / 298 (0.00%)
occurrences (all)	12	12	0
Proctitis gonococcal			
subjects affected / exposed	11 / 371 (2.96%)	15 / 369 (4.07%)	4 / 298 (1.34%)
occurrences (all)	15	20	5
Urethritis			
subjects affected / exposed	13 / 371 (3.50%)	16 / 369 (4.34%)	5 / 298 (1.68%)
occurrences (all)	14	21	5
Urinary tract infection			
subjects affected / exposed	12 / 371 (3.23%)	16 / 369 (4.34%)	3 / 298 (1.01%)
occurrences (all)	14	19	4
Influenza			
subjects affected / exposed	14 / 371 (3.77%)	18 / 369 (4.88%)	0 / 298 (0.00%)
occurrences (all)	14	18	0
COVID-19			
subjects affected / exposed	25 / 371 (6.74%)	76 / 369 (20.60%)	55 / 298 (18.46%)
occurrences (all)	25	79	57
Anal chlamydia infection			
subjects affected / exposed	22 / 371 (5.93%)	13 / 369 (3.52%)	0 / 298 (0.00%)
occurrences (all)	31	16	0
Chlamydial infection			
subjects affected / exposed	12 / 371 (3.23%)	21 / 369 (5.69%)	6 / 298 (2.01%)
occurrences (all)	12	23	6
Oropharyngeal gonococcal infection			
subjects affected / exposed	15 / 371 (4.04%)	16 / 369 (4.34%)	3 / 298 (1.01%)
occurrences (all)	16	22	3
Sinusitis			
subjects affected / exposed	15 / 371 (4.04%)	13 / 369 (3.52%)	2 / 298 (0.67%)
occurrences (all)	17	15	2
Conjunctivitis			

subjects affected / exposed	8 / 371 (2.16%)	16 / 369 (4.34%)	2 / 298 (0.67%)
occurrences (all)	10	19	2
Folliculitis			
subjects affected / exposed	14 / 371 (3.77%)	0 / 369 (0.00%)	0 / 298 (0.00%)
occurrences (all)	16	0	0
Gonorrhoea			
subjects affected / exposed	9 / 371 (2.43%)	12 / 369 (3.25%)	5 / 298 (1.68%)
occurrences (all)	10	15	7
Tonsillitis			
subjects affected / exposed	10 / 371 (2.70%)	8 / 369 (2.17%)	2 / 298 (0.67%)
occurrences (all)	12	13	2
Respiratory tract infection			
subjects affected / exposed	9 / 371 (2.43%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	9	11	1
Tooth infection			
subjects affected / exposed	10 / 371 (2.70%)	10 / 369 (2.71%)	7 / 298 (2.35%)
occurrences (all)	12	13	8
Urethritis gonococcal			
subjects affected / exposed	4 / 371 (1.08%)	15 / 369 (4.07%)	0 / 298 (0.00%)
occurrences (all)	4	16	0
Onychomycosis			
subjects affected / exposed	6 / 371 (1.62%)	10 / 369 (2.71%)	2 / 298 (0.67%)
occurrences (all)	7	11	2
Rhinitis			
subjects affected / exposed	2 / 371 (0.54%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	2	9	1
Fungal skin infection			
subjects affected / exposed	11 / 371 (2.96%)	8 / 369 (2.17%)	0 / 298 (0.00%)
occurrences (all)	13	10	0
Proctitis chlamydial			
subjects affected / exposed	0 / 371 (0.00%)	14 / 369 (3.79%)	2 / 298 (0.67%)
occurrences (all)	0	23	2
Suspected COVID-19			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	2 / 298 (0.67%)
occurrences (all)	0	9	2
Tinea versicolour			

subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	1 / 298 (0.34%)
occurrences (all)	0	11	1
Urethritis chlamydial			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	1 / 298 (0.34%)
occurrences (all)	0	11	1
Herpes zoster			
subjects affected / exposed	0 / 371 (0.00%)	8 / 369 (2.17%)	0 / 298 (0.00%)
occurrences (all)	0	8	0
Metabolism and nutrition disorders			
Vitamin D deficiency			
subjects affected / exposed	12 / 371 (3.23%)	22 / 369 (5.96%)	5 / 298 (1.68%)
occurrences (all)	15	23	5
Hypercholesterolaemia			
subjects affected / exposed	0 / 371 (0.00%)	9 / 369 (2.44%)	0 / 298 (0.00%)
occurrences (all)	0	9	0
Hyperlipidaemia			
subjects affected / exposed	0 / 371 (0.00%)	9 / 369 (2.44%)	1 / 298 (0.34%)
occurrences (all)	0	9	1
Abnormal loss of weight			
subjects affected / exposed	0 / 371 (0.00%)	10 / 369 (2.71%)	1 / 298 (0.34%)
occurrences (all)	0	10	2
Abnormal weight gain			
subjects affected / exposed	0 / 371 (0.00%)	12 / 369 (3.25%)	4 / 298 (1.34%)
occurrences (all)	0	12	4

Non-serious adverse events	Randomized to TBR but received TDF-based regimen(Early Switch)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypertension			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all) Chest pain subjects affected / exposed occurrences (all) Influenza like illness subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all)	 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0		
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	 0 / 1 (0.00%) 0		
Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all)	 0 / 1 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all)	 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0		
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Insomnia	 0 / 1 (0.00%) 0		

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Investigations			
Weight increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Arthropod bite			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Muscle strain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Limb injury			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			

Ear pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Dyspepsia			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Abdominal distension subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Proctalgia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Dental caries subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Gastritis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Dry skin subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Dermatitis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Rash subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Pruritus subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Renal and urinary disorders Dysuria			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Syphilis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Bronchitis			

subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Gastroenteritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Oral herpes				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Proctitis gonococcal				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Urethritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Urinary tract infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Influenza				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
COVID-19				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Anal chlamydia infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Chlamydial infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Oropharyngeal gonococcal infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Sinusitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Conjunctivitis				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Folliculitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Gonorrhoea				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Tonsillitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Respiratory tract infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Tooth infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Urethritis gonococcal				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Onychomycosis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Rhinitis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Fungal skin infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Proctitis chlamydial				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Suspected COVID-19				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences (all)	0			
Tinea versicolour				

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Urethritis chlamydial			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Herpes zoster			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Vitamin D deficiency			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypercholesterolaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hyperlipidaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abnormal loss of weight			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abnormal weight gain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 May 2017	Amendment 01: TAF was corrected by removal of the word "fumarate". Clarification was provided in the overall design to specify that participants randomized to TBR will switch to DTG/3TC FDC at Week 52 if human immunodeficiency virus-1 ribonucleic acid (HIV-1 RNA) <50 copies per milliliter (c/mL) at Week 48 (or upon retest by Week 52). Biomarkers of inflammation and mitochondrial function were removed as exploratory endpoints. A Week 96 endpoint was added to the measurement of biomarkers of telomerase function in a subset of participants. Cardiovascular biomarker measurements were removed as exploratory endpoints. Inclusion Criteria #5 was edited for clarity. Protocol Section 6.2, Protocol Permitted Substitutions, added. The text defining the TBR comparators as investigational medicinal product was removed; TBR comparators are provided in designated, specific countries only, as needed. The Time and Events Table was modified to clarify that whole blood samples could be utilized for virology and for telomere length measurements, and cryopreserved peripheral blood mononuclear cells (PBMCs) could be used to evaluate telomerase activity. Updated version of Division of acquires immunodeficiency syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (version 2.1), March 2017, was provided in Protocol Section 12.9. Changes were made to the protocol text to reflect the addition of Country Specific requirements for Japan.
13 June 2017	Amendment 02: The impetus for this protocol amendment was to update Protocol Appendix 5, Protocol Appendix 6 and Protocol Appendix 8 based on the ViiV Healthcare templates for these appendices that were appropriate for the HIV participant population.
24 August 2017	Amendment 03: Amended to include: Addition of cluster of differentiation 8 plus (CD8+) lymphocyte assessments, addition of inflammatory biomarkers assessments as new exploratory endpoints, and revision of the sample size based on updated estimates for the primary endpoint for the investigational arm.
07 December 2017	Amendment 04: Amended to include pharmacokinetics assessments in the DTG/3TC FDC arm as exploratory endpoints; to update exclusion criterion 18 and remove its corresponding secondary endpoint no longer relevant; and to add glycated hemoglobin (HbA1c) and homeostasis model of assessment-insulin resistance (HOMA-IR) assessments. For clarification purposes, the adverse event (AE) severity grading in Protocol Appendix 8 and Protocol Section 13.8.6 (Evaluating AEs and serious adverse events [SAEs]) were updated to be consistent with Protocol Appendix 9, Protocol Section 13.9 (Division of AIDS table for Grading Severity of Adult and Pediatric Adverse Events). This change has no impact on the investigator's evaluation of adverse events. Text was edited in Protocol Appendix 10, Protocol Section 13.10.2 to clarify wording for the country specific requirement for Japan.

14 June 2018	Amendment 05: Changes were made to the protocol to manage and mitigate risks following identification of a potential safety issue related to neural tube defects in infants born to women with exposure to DTG at the time of conception. Changes were also made to include updated text to address a higher number of participants screened than planned, to update references to the DTG Investigator's Brochure (IB) to reflect the most current versions and to add clarification and correct minor typos. The Risk Assessment table (Protocol Section 4.6.1) was updated to include language regarding risk and mitigation of neural tube defects. The withdrawal criteria (Protocol Section 5.4) were updated to include a reminder that females of reproductive potential who change their minds and desire to be pregnant, or who state they no longer are willing to comply with the approved pregnancy avoidance methods, would also be withdrawn from the study. The Time and Events table (Protocol Section 7.1) was updated to include a reminder for investigators to check at every visit that females of reproductive potential are avoiding pregnancy. The modified list of highly effective methods for avoiding pregnancy in females of reproductive potential (FRP) (Protocol Section 13.3.1) was updated to exclude the double barrier method of contraception, which does not meet the updated GlaxoSmithKline [GSK]/ViiV criteria for a highly effective method. The Type and Number of participants (Protocol Section 4.3) and Sample Size Assumptions (Protocol Section 9.2.1) were updated to address a higher number of participants screened than planned.
29 August 2018	Amendment 06: Changes were made to the protocol to update the study design to extend the Randomized Early Switch Phase through to 148 weeks instead of Week 52, delaying the late switch to Week 148 with long-term follow-up through to completion of the study at Week 200. The rationale for this change was to collect and assess long-term comparative efficacy and safety data for DTG/3TC FDC vs. a TAF-based regimen.
27 April 2020	Amendment 07: Changes were made to the protocol to introduce metabolic health exploratory objectives including metabolic syndrome, cardiovascular risk and other anthropomorphic measures to assess type and implication of weight change overtime. Additional on-treatment assessments from Week 144 through Week 196, include resting blood pressure, waist circumference and hip circumference. Changes were also made to include an additional appendix to provide standardized procedural guidance on obtaining the above mentioned measurements. A missing assessment of concomitant medication at Week 148 was also corrected. Results from the Botswana outcome surveillance study were updated for DTG and neural tube defects.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported